Archive for August, 2013

(IMOS) DECLARES US$0.14 CASH DIVIDEND

HSINCHU, Aug. 30, 2013 — Board of Director of ChipMOS TECHNOLOGIES (Bermuda) LTD. (“ChipMOS” or the “Company”) (Nasdaq: IMOS), an industry leading provider of outsourced semiconductor assembly and test services (“OSAT”), today declared a cash dividend of US$0.14 per share payable on October 30, 2013 to all common shareholders of record at the close of business on October 16, 2013.

S.J. Cheng, Chairman and Chief Executive Officer of ChipMOS, said, “The dividend declaration is a direct reflection of the Company’s financial strength and confidence in our growth prospects.  This represents another step in our ongoing efforts to build shareholder value. We continue to execute on our business, improve profitability, and outperform the industry due to our differentiated end market exposure and customer alignment within our target markets.”

About ChipMOS TECHNOLOGIES (Bermuda) LTD.:

ChipMOS TECHNOLOGIES (Bermuda) LTD. (“ChipMOS” or the “Company”) (NASDAQ: IMOS) (http://www.chipmos.com) is an industry leading provider of semiconductor testing and assembly services. With advanced facilities in Hsinchu and Southern Taiwan Science Parks in Taiwan and Shanghai, ChipMOS and its subsidiaries provide testing and assembly services to a broad range of customers, including leading fabless semiconductor companies, integrated device manufacturers and independent semiconductor foundries.  The Company’s majority-owned subsidiary, ChipMOS TECHNOLOGIES INC. (“ChipMOS Taiwan”), is listed on the Gre Tai Securities Market under Stock Ticker 8150.

Forward-Looking Statements

Certain statements contained in this announcement may be viewed as “forward-looking statements” within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual performance, financial condition or results of operations of the Company to be materially different from any future performance, financial condition or results of operations implied by such forward-looking statements. Further information regarding these risks, uncertainties and other factors is included in the Company’s most recent Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the “SEC”) and in the Company’s other filings with the SEC.

Contacts:
In TaiwanDr. S.K. Chen

ChipMOS TECHNOLOGIES (Bermuda) LTD.

+886-6-507-7712

s.k._chen@chipmos.com

In the U.S.David Pasquale

Global IR Partners

+1-914-337-8801

dpasquale@globalirpartners.com

Friday, August 30th, 2013 Uncategorized Comments Off on (IMOS) DECLARES US$0.14 CASH DIVIDEND

(LNCO) Monthly Distribution and Dividend

HOUSTON, Aug. 30, 2013 — LINN Energy, LLC (Nasdaq:LINE) and LinnCo, LLC (Nasdaq:LNCO) announced today monthly distributions and dividends, respectively.

LINN Energy, LLC declared a monthly cash distribution of $0.2416 per unit, or $2.90 per unit on an annualized basis, for all of its outstanding units. The distribution will be payable September 13, 2013, to unitholders of record as of the close of business on September 10, 2013.

LinnCo, LLC declared a monthly cash dividend of $0.2416 per common share, or $2.90 per share on an annualized basis, for all of its outstanding common shares. The dividend will be payable September 16, 2013, to shareholders of record as of the close of business on September 10, 2013.

ABOUT LINN ENERGY

LINN Energy’s mission is to acquire, develop and maximize cash flow from a growing portfolio of long-life oil and natural gas assets.  LINN Energy is a top-15 U.S. independent oil and natural gas development company, with approximately 4.8 Tcfe of proved reserves in producing U.S. basins as of December 31, 2012. More information about LINN Energy is available at www.linnenergy.com.

ABOUT LINNCO

LinnCo was created to enhance LINN Energy’s ability to raise additional equity capital to execute on its acquisition and growth strategy. LinnCo is a Delaware limited liability company that has elected to be taxed as a corporation for United States federal income tax purposes, and accordingly its shareholders will receive a Form 1099 in respect of any dividends paid by LinnCo. More information about LinnCo is available at www.linnco.com.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS

This press release includes “forward-looking statements.” All statements, other than statements of historical facts, included in this press release that address activities, events or developments that the company expects, believes or anticipates will or may occur in the future are forward-looking statements. These statements include, but are not limited to forward-looking statements about acquisitions, timing and payment of distributions, and the expectations of plans, strategies, objectives and anticipated financial and operating results of the company, including the company’s drilling program, production, hedging activities, capital expenditure levels and other guidance included in this press release. These statements are based on certain assumptions made by the company based on management’s experience and perception of historical trends, current conditions, anticipated future developments and other factors believed to be appropriate. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the company, which may cause actual results to differ materially from those implied or expressed by the forward-looking statements. These include risks relating to the company’s financial performance and results, availability of sufficient cash flow to pay distributions and execute its business plan, prices and demand for oil, natural gas and natural gas liquids, the ability to replace reserves and efficiently develop current reserves and other important factors that could cause actual results to differ materially from those projected as described in the company’s reports filed with the Securities and Exchange Commission. See “Risk Factors” in the company’s Annual Report filed on Form 10-K and other public filings and press releases.

Any forward-looking statement speaks only as of the date on which such statement is made and the company undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise.

CONTACT: LINN Energy, LLC and LinnCo, LLC

         Investors & Media:
         Clay Jeansonne, Vice President, Investor and Public Relations
         281-840-4193
Friday, August 30th, 2013 Uncategorized Comments Off on (LNCO) Monthly Distribution and Dividend

(TKMR) Publications on Lipid Nanoparticle Technology Highlighted

Published Data Shows 100% Protection Against Multiple Strains of Marburg Virus in Animal Model Using RNAi Therapeutic Developed by Tekmira and Its Collaborators

ALN-TTR Results Enabled by Tekmira’s LNP Technology as Highlighted in the New England Journal of Medicine Provide Robust Proof of Concept for RNAi Therapy in Man

VANCOUVER, British Columbia, Aug. 30, 2013 — Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced the publication of two articles in peer-reviewed scientific journals – the Journal of Infectious Diseases and New England Journal of Medicine – that highlight results enabled by Tekmira’s lipid nanoparticle (LNP) technology.

“These recently published data further validate the broad applicability of Tekmira’s industry-leading LNP technology platform. Our work with our collaborators at UTMB has resulted in the first report of complete post-exposure protection against the most pathogenic strain of Marburg virus. These findings build upon our work in infectious diseases – including our TKM-Ebola program, an anti-Ebola viral therapeutic currently in development under a $140 million contract awarded by the U.S. Government and entering a Phase I clinical trial early in 2014 – and provide a foundation for future infectious disease therapeutics,” said Dr. Mark J. Murray, Tekmira’s President and CEO.

“Tekmira’s LNP technology is also enabling the rapid, dose-dependent, durable, and specific knockdown of TTR in clinical trials of Alnylam’s ALN-TTR01 and ALN-TTR02 RNAi therapeutic products. Specifically, the ALN-TTR02 data points to our LNP delivery technology providing improved potency and demonstrating up to a 94% reduction of serum TTR with ALN-TTR02,” added Dr. Murray.

The study published in the Journal of Infectious Diseases results from a collaboration between Tekmira and the University of Texas Medical Branch (UTMB). The paper, entitled “Protection against Lethal Marburg Virus Infection Mediated by Lipid Encapsulated siRNA” showed 100% protection in guinea pig models against the Angola, Ci67 and Ravn strains of the Marburg virus using a broad spectrum RNAi therapeutic enabled by Tekmira’s LNP (Ursic-Bedoya et al., J Infect Dis. (2013) [Online early access]. doi: 10.1093/infdis/jit465. First published online: August 29, 2013).

In 2010, Tekmira and UTMB were awarded a National Institutes of Health (NIH) grant to support research to develop RNAi therapeutics to treat Ebola and Marburg hemorrhagic fever viral infections. The grant is supporting ongoing work at Tekmira and at UTMB including work advancing these promising results into non-human primates.

Complete study results from Phase I trials with ALN-TTR01 and ALN-TTR02 were published in the New England Journal of Medicine in a paper entitled “Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis” (Coelho et al., N Engl J Med 2013; 369:819-29). ALN-TTR01 and ALN-TTR02 are systemically delivered RNAi therapeutics that use Tekmira’s LNP technology and target transthyretin (TTR), the disease-causing protein in TTR-mediated amyloidosis (ATTR). ALN-TTR01 and ALN-TTR02 are being developed by Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY). More detailed information about the Phase I trials with ALN-TTR01 and ALN-TTR02 can be found in Alnylam’s news release dated August 28, 2013, which has been posted at www.alnylam.com.

Tekmira has granted Alnylam a license to use Tekmira’s LNP technology to advance RNAi therapeutic products, and Tekmira is eligible to receive milestones and royalties as Alnylam’s LNP enabled products are developed and commercialized. Tekmira is entitled to receive a $5 million milestone payment when ALN-TTR02 enters a pivotal or Phase III clinical trial, which Alnylam has guided should occur by the end of 2013. Tekmira is eligible to receive royalty payments based on commercial sales of ALN-TTR02.

About RNAi and Tekmira’s LNP

RNAi therapeutics have the potential to treat a broad number of human diseases by “silencing” disease causing genes. The discoverers of RNAi, a gene silencing mechanism used by all cells, were awarded the 2006 Nobel Prize for Physiology or Medicine. RNAi therapeutics, such as “siRNAs,” require delivery technology to be effective systemically. Tekmira believes its LNP technology represents the most widely adopted delivery technology for the systemic delivery of RNAi therapeutics. Tekmira’s LNP platform is being utilized in multiple clinical trials by both Tekmira and its partners. Tekmira’s LNP technology (formerly referred to as stable nucleic acid-lipid particles or SNALP) encapsulates siRNAs with high efficiency in uniform lipid nanoparticles that are effective in delivering RNAi therapeutics to disease sites in numerous preclinical models. Tekmira’s LNP formulations are manufactured by a proprietary method which is robust, scalable and highly reproducible, and LNP-based products have been reviewed by multiple FDA divisions for use in clinical trials. LNP formulations comprise several lipid components that can be adjusted to suit the specific application.

About Tekmira

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing novel RNAi therapeutics and providing its leading lipid nanoparticle delivery technology to pharmaceutical partners. Tekmira has been working in the field of nucleic acid delivery for over a decade and has broad intellectual property covering LNPs. Further information about Tekmira can be found at www.tekmirapharm.com. Tekmira is based in Vancouver, B.C.

Forward-Looking Statements and Information

This news release contains “forward-looking statements” or “forward-looking information” within the meaning of applicable securities laws (collectively, “forward-looking statements”). Forward-looking statements are generally identifiable by use of the words “believes,” “may,” “plans,” “will,” “anticipates,” “intends,” “budgets,” “could,” “estimates,” “expects,” “forecasts,” “projects” and similar expressions, and the negative of such expressions. Forward-looking statements in this news release include Tekmira’s strategy, future operations, clinical trials, prospects and the plans of management; RNAi (ribonucleic acid interference) product development programs; Tekmira’s collaboration with UTMB; the first reported results of complete post-exposure protection against the most pathogenic strain of Marburg virus; the expected initiation of a Phase I clinical trial for TKM-Ebola; Alnylam’s ALN-TTR product development programs; the development timeline and expected milestone payments associated with Alnylam’s ALN-TTR program; the advancement of products that utilize Tekmira’s lipid nanoparticle technology; expectations regarding the advancement of multiple product candidates; the quantum and timing of further clinical data being presented for LNP-enabled products; continued innovation and protection of LNP technology; timing of the initiation of clinical trials and release of clinical data from Tekmira’s product candidates; the quantum and timing of potential milestone and royalty payments; and the use of lipid nanoparticle technology by Tekmira’s licensees.

With respect to the forward-looking statements contained in this news release, Tekmira has made numerous assumptions regarding, among other things: LNP’s status as a leading RNAi delivery technology; the effectiveness of Tekmira’s products as a treatment for infectious disease, or other diseases; results in preclinical models are indicative of the potential effect in humans; Tekmira’s research and development capabilities and resources; FDA approval with respect to commencing clinical trials; the timing and obtaining of regulatory approvals for Tekmira’s products; the timing and results of clinical data releases and use of LNP technology by Tekmira’s development partners and licensees; the time required to complete research and product development activities; the timing and quantum of payments to be received under contracts with Tekmira’s partners, including Alnylam; Tekmira’s financial position and its ability to execute on its business strategy; and Tekmira’s ability to protect its intellectual property rights and not to infringe on the intellectual property rights of others. While Tekmira considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.

Additionally, there are known and unknown risk factors which could cause Tekmira’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained herein. Known risk factors include, among others: Tekmira’s research and development capabilities and resources may not meet current or expected demand; Tekmira’s products may not prove to be effective in the treatment of infectious disease, or other diseases; Tekmira may not obtain and protect intellectual property rights, and operate without infringing on the intellectual property rights of others; Tekmira may face competition from other pharmaceutical or biotechnology companies and the possibility that other organizations have made advancements in RNAi delivery technology that Tekmira is not aware of; pre-clinical and clinical trials may be more costly or take longer to complete than anticipated and may not generate results that warrant future development of the tested drug candidate; the FDA may determine that the design and planned analysis of Tekmira’s clinical trials do not adequately address the trial objectives in support of Tekmira’s regulatory submissions; the FDA may not approve the commencement of Tekmira’s planned clinical trials or approve the use of Tekmira’s products; Tekmira may not initiate a new TKM-Ebola Phase I clinical trial in the anticipated timeframe, or at all; Tekmira’s development partners and licensees conducting clinical trial, development programs and joint venture strategic alliances may not result in expected results on a timely basis, or at all; a Phase III or pivotal trial for ALN-TTR02 may not start as currently anticipated, or at all; expected milestone or royalty payments from Alnylam may not be received in the quantum and on the timing currently anticipated, or at all; future operating results are uncertain and likely to fluctuate; Tekmira may not be able to raise additional financing required to fund further research and development, clinical studies, and obtain regulatory approvals, on commercially acceptable terms or at all; economic and capital market conditions; Tekmira may become subject to product liability or other legal claims for which Tekmira has made no accrual in its financial statements; and the possibility that Tekmira may not have sufficiently budgeted for expenditures necessary to carry out planned activities.

A more complete discussion of the risks and uncertainties facing Tekmira appears in Tekmira’s annual report on Form 20-F for the year ended December 31, 2012 (Annual Report), which is available at www.sedar.com or at www.sec.gov/edgar.shtml. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Tekmira disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.

CONTACT: Investors
         Jodi Regts
         Director, Investor Relations
         Phone: 604-419-3234
         Email: jregts@tekmirapharm.com

         Media
         David Ryan
         Longview Communications Inc.
         Phone: 416-649-8007
         Email: dryan@longviewcomms.ca
Friday, August 30th, 2013 Uncategorized Comments Off on (TKMR) Publications on Lipid Nanoparticle Technology Highlighted

(GENE) Receives Certification for New York State

MELBOURNE, AUSTRALIA–(Aug 30, 2013) – Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) is pleased to announce that it has received its Clinical Laboratory Permit from the New York State Department of Health (“DoH”). In late July, the Company’s Melbourne laboratories were inspected under New York’s DoH Clinical Laboratory Evaluation Program (“CLEP”) and, following the two-day audit, it subsequently received a Laboratory Evaluation Report with “No significant deficiencies”. Thus, the permit was able to be issued immediately.

This permit allows the Company to test BREVAGen™ from residents of New York State — a densely populated state of nearly 20 million people — and completes the out of state licensures allowing the Company to provide testing services to all 50 US states. The Company can now meet requests received from New York physicians to provide the BREVAGen™ test to patients as part of their clinical practice. Phenogen Sciences Inc. (Genetic Technologies’ US subsidiary) will be appointing representatives in the near future to cover this state, with a particular emphasis on New York City.

The addition of this important territory will augment the current market adoption, which the Company notes is delivering significant increases in the number of test samples provided to the laboratory during the current quarter to date.

“This is a wonderful endorsement of the quality of our laboratory systems and the validation package provided by our highly qualified staff,” said CEO, Ms. Alison Mew. “Importantly, it also allows women across the United States access to BREVAGen™ to deliver comprehensive breast health care.”

About Genetic Technologies Limited
Genetic Technologies is an established diagnostics company with more than 20 years of experience in commercializing genetic testing, non-coding DNA and product patenting. The Company has operations in Australia and the U.S. and is dual-listed on the ASX (Code: GTG) and NASDAQ (Ticker: GENE). Genetic Technologies is focused on the commercialization of its patent portfolio through an active out-licensing program and the global expansion of its oncology and cancer management diagnostics assets. Its U.S. subsidiary, Phenogen Sciences Inc., offers novel predictive testing and assessment tools to help physicians proactively manage women’s health. Phenogen’s lead product, BREVAGen™, is a first in class, clinically validated risk assessment test for non-familial breast cancer.

For more information, please visit http://www.gtglabs.com and http://www.phenogensciences.com

Safe Harbor Statement
Any statements in this press release that relate to the Company’s expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company’s actual results may differ materially from expected results. Additional risks associated with Genetic Technologies’ business can be found in its periodic filings with the SEC.

FOR FURTHER INFORMATION PLEASE CONTACT
Ms. Alison J. Mew
Chief Executive Officer
Genetic Technologies Limited
Phone: +61 3 8412 7000

Laura Forman (USA)
Blueprint Life Science Group
+1 (415) 375 3340, Ext. 103

Friday, August 30th, 2013 Uncategorized Comments Off on (GENE) Receives Certification for New York State

(ECTE) Platinum-Montaur Proposal to Bolster Echo Therapeutics Stock

NEW YORK, Aug. 30, 2013 – Platinum-Montaur Life Sciences, LLC (“Platinum”), the largest shareholder of Echo Therapeutics, Inc. (Nasdaq: ECTE) (“Echo” or the “Company”) with approximately 20% of the outstanding common stock of the Company, today sent a letter to the Board of Directors of Echo (the “Board”) outlining Platinum’s proposals to stop the destruction of shareholder value.

Echo’s share price has collapsed over 95% in the last two years.

“We have diligently attempted on numerous occasions to work constructively with the Board,” stated Michael Goldberg, M.D., Portfolio Manager at Platinum.  “Regrettably, endless months of Board inaction force us to publicly announce a multi-point plan carefully targeted to address the shortfalls in leadership, strategy, product partnering and financing that have plagued Echo and punished its shareholders through dilution and rampant loss of market value.”

Platinum’s letter to the Board, reproduced below, proposes an immediate plan that:

  • Removes ineffective directors and replaces them with professionals who bring key industry experience and informed investor community insight to a Board that has proven incapable of developing Echo’s potentially groundbreaking CGM Technology and in communicating with the shareholder base
  • Presents a uniquely valuable opportunity to team with an offshore partner who will bear the burden of developing and marketing the CGM Technology on economically favorable terms
  • Engages a premier consulting firm to help the new Board establish and implement a sorely needed strategic vision
  • Retains a leading recruiting firm to hire a gifted permanent CEO with bona fide medical device development credentials who is not tainted by service on the current underperforming Board
  • Offers financing at a premium to share price that will halt the dilution that has battered the shareholder owners of Echo

Shareholders are strongly urged to read Platinum’s letter to the Board in its entirety and draw their own conclusions about whether this proposal is right for the Company.

Platinum urges the Board to quickly work through the proposal and stands ready to assist in any way it can.  It believes that the Company has a potentially transformative product in the CGM Technology that needs to be developed without further waste of time and money.  The Board must show the market that it is no longer business as usual at Echo.  As the letter to the Board makes clear, Platinum’s proposal expires at 5 PM on Wednesday, September 4, 2013 unless accepted by the Board before then.  If the Board once again lets another prime opportunity go by, Platinum reserves all it rights to take further action.

Letter to the Board

August 30, 2013

Board of Directors
Echo Therapeutics, Inc.
8 Penn Center
1628 JFK Boulevard, Suite 300
Philadelphia, PA  19103

Gentlemen:

I write to you on behalf of Platinum-Montaur Life Sciences, LLC and our affiliated funds, beneficial holders of approximately 20% percent of the common stock of Echo Therapeutics, Inc. (the “Company” or “Echo”).  For many months now we have attempted to have a constructive dialog with the Board of Directors of Echo (the “Board”) and its former CEO who was recently and summarily terminated.  Not once in our numerous discussions has a director or executive of Echo acknowledged the Company’s free-fall and their role in it.  Do the people in Echo’s c-suite and Board room not recognize the judgment that the investing public is rendering on their leadership and oversight when the stock price plummets approximately 95% in the past two years while the NASDAQ has increased approximately 40%?   To this day we are still waiting for the Company’s leadership to assuage the market’s deepest concerns and publicly announce a plausible and immediate strategy for turning Echo around and unlocking its awesome potential.

Frankly, we would have thought you would be reaching out to shareholders and welcoming and acting on the positive ideas suggested by Platinum and others.  However, the Board’s terminal inaction convinces us that you cannot or will not right this ship without outside pressure and leadership.  We cannot wait any more, and we sense that other shareholders feel the same way.  We must now publicly advance a proposal that we believe provides a real lifeline to this troubled but potentially fantastic Public Company.

The following is a summary of our proposal:

1.         Board Composition:

a.         Vincent D. Enright and James F. Smith must resign immediately from the Board.

b.         Michael M. Goldberg, M.D. and Gary Saxton (an experienced medical device executive who has negotiated deals with many medical device companies) should be immediately appointed to the Board.

2.         Development of CGM Technology:  We have identified a potential partner (“China Partner”) for the Company for the development and manufacture of the CGM Product in China.  The Board should begin discussions with China Partner without delay.  It is anticipated that an agreement with China Partner would include:

a.         Fast Track CFDA approval of the Product;

b.         China Partner covering the entire development cost and taking responsibility for manufacturing, marketing and selling the approved Product in China;

c.         China Partner would have exclusivity for the Product in mainland China;

d.         China Partner and the Company would  split sales of the Product in China based on a high double-digit royalty arrangement; China Partner will pay all manufacturing, sales and marketing, and distribution costs from its share after the payment of royalties to Echo;

e.         The Company will retain all intellectual property; and

f.          Upon earlier of (i) approval of the Product by CFDA, or (ii) termination of the agreement with China Partner, the Company will reimburse China Partner for $1.5 million of expenses in the form of common stock of the Company (valued at a mutually acceptable price to be determined).

3.         Engagement of Consultant: The Company will engage a consulting firm, to be unanimously approved by the Board, to provide strategic consulting to the Company, including an independent, high-quality review of the Company’s product and business development positioning.  We have a candidate we would like to suggest for this role.

4.         Engagement of a Recruiting Firm.  Immediately hire a top quality executive recruiting firm with recent relevant exposure to executives with current experience in medical device business development.

5.         Future Investment: The Company will not enter into any further equity or debt financing or business development opportunities without the unanimous approval of the newly constituted Board.  Upon closing of the transaction with China Partner, we (and potentially other co-investors approved by the Board) will purchase $10 million of common stock of the Company (valued at a mutually acceptable price to be determined).  Continued depletion of cash through an uncorrected burn rate will of course negatively impact price.

Now is the time to act.  Surely the Board sees that each day it looks at the stock price and the burn rate.  Yes, you were elected by the shareholders.  Now show that their trust was justified by forcefully and publicly acting in their best interests.  Reach out to your largest shareholders and ask them what they think of this Proposal.  We stand ready to speak or meet with you to help in any way we can, and will make necessary introductions to China Partner.  However, we do expressly want a public response to this entirely sound proposal, and call upon the Board to provide that response no later than 5 PM on Wednesday, September 4, 2013 (the “Deadline”).  If the Board fails to accept our Proposal by the Deadline, then Platinum’s willingness to participate in the Proposal will expire and we expressly reserve all our rights, including by taking our case directly to our fellow shareholders.  As we have publicly expressed in the past, we reserve all rights.

Best regards,

Michael M. Goldberg, M.D.
Portfolio Manager

About Platinum-Montaur Life Sciences, LLC

Platinum-Montaur Life Sciences, LLC is the healthcare division of Platinum Partners, a New York-based investment management group with more than $1 billion in assets under management.  Platinum-Montaur  Life Sciences, LLC employs a growth equity investment strategy, taking large early-stage positions in public and private companies with promising healthcare technologies.

Safe Harbor

Cautionary Statement Regarding Forward-Looking Statements

The information herein contains “forward-looking statements.” Specific forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts and include, without limitation, words such as “may,” “will,” “expects,” “believes,” “anticipates,” “plans,” “estimates,” “projects,” “targets,” “forecasts,” “seeks,” “could” or the negative of such terms or other variations on such terms or comparable terminology. Similarly, statements that describe our objectives, plans or goals are forward-looking. Our forward-looking statements are based on our current intent, belief, expectations, estimates and projections regarding the Company and projections regarding the industry in which it operates. These statements are not guarantees of future performance and involve risks, uncertainties, assumptions and other factors that are difficult to predict and that could cause actual results to differ materially. Accordingly, you should not rely upon forward-looking statements as a prediction of actual results.

CONTACT: Alan Oshiki, Broadgate Consultants, 212-232-2354, aoshiki@broadgate.com

Friday, August 30th, 2013 Uncategorized Comments Off on (ECTE) Platinum-Montaur Proposal to Bolster Echo Therapeutics Stock

(HOTR) Hooters Honors NASCAR Heritage, Sponsors Nelson Piquet, Jr., in Chicagoland

Hooters of America, LLC, and Chanticleer Holdings, Inc. (NASDAQ:HOTR), a franchisee of international Hooters locations, today announced Hooters is sponsoring Nelson Piquet, Jr.’s No. 30 Chevrolet Camaro in the NASCAR Nationwide Series (NNS) race at Chicagoland Speedway on Sept. 14. The No. 30 car sponsorship celebrates Hooters 30th anniversary year, honoring the iconic legacy of the brand and continued growth as one of the most successful dining destinations in the world.

Nelson Piquet, Jr., unveiled Hooters as the sponsor of his No. 30 Chevrolet Camaro for Chicagoland S ... Nelson Piquet, Jr., unveiled Hooters as the sponsor of his No. 30 Chevrolet Camaro for Chicagoland Speedway on Sept. 14. The No. 30 car sponsorship celebrates Hooters 30th anniversary year. The sleek design features the new, modern Hootie owl logo, the iconic Hooters orange and white color scheme and is modeled to pay homage to the famous No. 7 car of the late NASCAR champion and Hooters-sponsored driver, Alan Kulwicki. (Photo: Business Wire)

The 27-year-old driver, who is competing in his first full season in the NNS for Turner Scott Motorsports, became the first Brazilian to win in one of NASCAR’s top-three national touring series events when he took the checkered flag last year at Road America. Piquet Jr. went on to win two more races in the NASCAR Camping World Truck Series in 2012, while also earning the series’ Most Popular Driver and Most Improved Driver awards. Piquet Jr. is a former Formula One driver and is the son of three-time Formula One world champion, Nelson Piquet.

“With a talented driver like Piquet, Jr., his international presence and a venue like Chicagoland, Hooters is proud to represent the number 30 car as we celebrate our 30th birthday this fall,” said Dave Henninger, chief marketing officer, Hooters of America. “The sponsorship gives us a special opportunity to showcase the contemporary evolution of Hooters, while paying tribute to our rich history that includes a longstanding relationship within the sport of stock car racing.”

Part of the Hooters evolution is the expansion of the casual dining restaurant brand into international markets. Chanticleer Holdings, which secured exclusive rights to operate Hooters restaurants in parts of Brazil earlier this year, plans to announce its first Brazil location in the near future.

“Hooters is such an iconic brand and has a rich history in the sport of stock car racing,” Piquet Jr. said. “It’s truly an honor to celebrate Hooters’ first 30 years and also the brand’s growth in global markets like my home country of Brazil.”

The official No. 30 Hooters car design was first revealed to the NASCAR world today via Piquet, Jr.’s Twitter account @nelsonpiquet. After a series of Hooters clues, Piquet, Jr., unveiled the sleek design that will hit the racetrack in Chicago with the new, modern Hootie owl logo. The design is an intentional nod to the past, painted in the iconic Hooters orange and white color scheme and modeled to pay homage to the famous No. 7 car of the late NASCAR champion and Hooters-sponsored driver, Alan Kulwicki.

This year also marks 20 years since a tragic airplane accident took the lives of Kulwicki along with Hooters executives Mark Brooks, Dan Duncan and Charlie Campbell. Dedicated to preserving their memory, Hooters will host the 20th annual Hooters Memorial Cup Golf Tournament on Sept. 16, two days after the Chicagoland race, in Marietta, Ga. This special fundraising event has helped generate more than $8 million to-date for the Hooters Community Endowment Fund (HOO.C.E.F.), which contributes to many of Hooters philanthropic endeavors.

In November 1992, just months before the accident, one of Hooters fondest NASCAR memories occurred as Kulwicki took second place in the season-ending Hooters 500 at Atlanta Motor Speedway to clinch the Winston Cup Championship by a mere 10 points, the closest margin in NASCAR history at the time. The race is often regarded as one of the best in NASCAR history, marking the final start in the career of legendary driver, Richard Petty, and series debut for future champion, Jeff Gordon.

To request interviews with Hooters, Piquet or to find photos of the Hooters No. 30 car, visit the Hooters newsroom at http://news.hooters.com.

About Hooters of America, LLC

Hooters of America, LLC is the franchisor and operator of more than 412 Hooters restaurants in 44 states and 27 foreign countries. The first Hooters opened in 1983 in Clearwater, Florida. Everyone is liberated from the ordinary at Hooters while enjoying great food, fun and uniquely-Hooters service from the iconic Hooters Girls. For more information about Hooters visit www.Hooters.com or follow us at www.twitter.com/Hooters or www.Facebook.com/Hooters.

About Chanticleer Holdings, Inc.

Chanticleer Holdings (HOTR) is focused on expanding the Hooters® casual dining restaurant brand in international emerging markets. Chanticleer currently owns in whole or part of the exclusive franchise rights to develop and operate Hooters restaurants in South Africa, Hungary and parts of Brazil, and has joint ventured with the current Hooters franchisee in Australia, while evaluating several additional international opportunities. The Company currently owns and operates in whole or part of six Hooters restaurants in its international franchise territories: Durban, Johannesburg, Cape Town and Emperor’s Palace in South Africa; Campbelltown in Australia; and Budapest in Hungary.

In 2011, Chanticleer and a group of noteworthy private equity investors, which included H.I.G. Capital, KarpReilly, LLC and Kelly Hall, president of Texas Wings Inc., the largest Hooters franchisee in the United States, acquired Hooters of America, a privately held company. Today, Hooters of America is an operator and the franchisor of over 430 Hooters® restaurants in 28 countries. Chanticleer maintains a minority ownership stake in Hooters of America and its CEO, Mike Pruitt, is also a member of Hooters’ Board of Directors.

For further information, please visit www.chanticleerholdings.com.

Facebook: www.Facebook.com/ChanticleerHOTR

Twitter: http://Twitter.com/ChanticleerHOTR

Friday, August 30th, 2013 Uncategorized Comments Off on (HOTR) Hooters Honors NASCAR Heritage, Sponsors Nelson Piquet, Jr., in Chicagoland

(GOGO) Marks 5th Anniversary of Commercial Aviation Connectivity Service

Surpasses 40 Million Connectivity Sessions Since Launch

ITASCA, Ill., Aug. 29, 2013  — (NASDAQ: GOGO) Gogo, the world leader of in-flight connectivity and a pioneer in wireless in-flight digital entertainment solutions, celebrates the fifth year anniversary of its first Internet enabled commercial flight this month.

Five years ago, Gogo revolutionized the in-flight experience by offering an Air-To-Ground, cellular based network that enabled passengers to connect to the Internet above 30,000 feet and traveling at speeds in excess of 500 miles-per-hour.  Today, more than a million passengers a month use the service to stay connected in-flight. Gogo’s connectivity service can now be found on nearly 2,000 commercial aircraft over nine major airline partners.  More than 7,000 commercial flights each day are connected using Gogo’s service.

“When Gogo launched its service five years ago, it was our cutting edge air to ground technology that allowed us to not only bring the Internet to the sky, it offered a scalable technology solution that was economically viable for the aviation industry and effectively opened the door for in-air connectivity to reach the traveling public,” said Gogo president and CEO, Michael Small. “Today, we continue to push the envelope in developing new technologies that leverage both our air to ground based service and satellite services to lead the way at bringing more bandwidth for the buck for the commercial aviation industry.”

In addition to connectivity related services, Gogo also launched its Gogo Vision product, which allows passengers to rent from a library of more than 100 movies and television shows and stream them to their own Wi-Fi enabled device.

“Gogo will continue to work with its airline partners to create products and services that will keep passengers connected, informed and entertained while in-flight,” added Small.

Gogo compiled a list of key milestones that cover the five year history of their connectivity service in an infographic that can be found here.

About Gogo

Gogo is the global leader of in-flight connectivity and wireless in-flight digital entertainment solutions. Using Gogo’s exclusive products and services, passengers with Wi-Fi enabled devices can get online on nearly 2,000 Gogo equipped commercial aircraft. In-flight connectivity partners include American Airlines, Air Canada, AirTran Airways, Alaska Airlines, Delta Air Lines, Frontier Airlines, United Airlines, US Airways and Virgin America. In-flight entertainment partners include American Airlines, Delta Air Lines, Scoot and US Airways. In addition to its commercial airline business, Gogo has more than 6,500 business aircraft outfitted with its communications services.

Back on the ground, Gogo’s 600+ employees in Itasca, IL, Broomfield, CO and London are working to continually redefine flying as a productive, socially connected, and all-around more satisfying experience. Connect with Gogo at www.gogoair.com, on Facebook at www.facebook.com/gogo and on Twitter at www.twitter.com/gogo.

Media Relations Contact: Investor Relations Contact:
Steve Nolan Varvara Alva
630-647-1074 630-647-7460
pr@gogoair.com ir@gogoair.com
Thursday, August 29th, 2013 Uncategorized Comments Off on (GOGO) Marks 5th Anniversary of Commercial Aviation Connectivity Service

(RSOL) to Deploy 1.1 MW Solar Power System for Ironhouse Sanitary District

Solar Project Expected to Reduce Electricity Costs by More Than $5.9 Million Over the Next 25 Years

LOUISVILLE, Colo., Aug. 29, 2013 — RGS Energy, the commercial and utility division of Real Goods Solar, Inc. (Nasdaq:RSOL), has been selected by Ironhouse Sanitary District (ISD) to deploy a 1.1 megawatt (MW) solar power system at its water recycling facility and administration building in Oakley, California.

RGS Energy will design, install, monitor and maintain the solar power system at the water recycling facility and the administration building. The installation will be comprised of a 1 MW single-axis tracking system and 60 kilowatt carport system, which will generate more than 2.3 million kilowatt hours of solar electricity per year to power the facilities. Construction is scheduled to begin in the fall of 2013 and be completed in the first quarter of 2014.

ISD’s current electrical cost for these facilities is more than $600,000 per year, but harnessing energy from the sun is expected to reduce the company’s cost of electricity by at least $95,000 in the first year alone, with a total savings of more than $5.9 million over the next 25 years. Over that 25 year period, the solar energy produced is expected to offset more than 89 million pounds of carbon dioxide emissions, or equivalent to taking more than 8,400 cars off the road (per EPA-based data).

RGS Energy’s financing partner, Smart Energy Capital, brokered a power purchase agreement between ISD and Constellation Energy Group, an energy supplier and business unit of Exelon. The agreement allows ISD to purchase the solar energy generated on site at less than market rates while funding 100% of the installation cost.

“RGS Energy showed us how going solar can be a sound and easily affordable investment, while providing significant environmental benefits to the community we serve,” said Jenny Skrel, ISD’s district engineer. “This new solar power system will drastically reduce our electrical costs and decrease our carbon footprint, while requiring zero capital to implement.”

Tim Seamans, RGS Energy’s general manager, commented: “We are proud to bring 100% clean renewable energy to the Ironhouse Sanitary District facilities. They are a perfect example of how a water recycling district can better serve the community by trimming costs and being good stewards of the environment.”

About Ironhouse Sanitary District
In existence since 1945, Ironhouse Sanitary District (ISD), located in Oakley, California, utilizes a staff of 32 field and office personnel to maintain sanitary services for nearly 38,000 customers in the Oakley and Bethel Island area. The district treats approximately 2.5 million gallons of wastewater every day at its modern treatment facility. Reclaimed water is applied to 334 acres of agricultural land on Jersey Island and discharged into the San Joaquin River. For more information, visit www.ironhousesanitarydistrict.com.

About Real Goods Solar and RGS Energy
Real Goods Solar, Inc. (RSOL) is one of the nation’s pioneering solar energy companies serving commercial, residential, and utility customers. Beginning with one of the very first photovoltaic panels sold to the public in the U.S. in 1978, the company has installed more than 15,000 solar power systems representing well over 100 megawatts of 100% clean renewable energy. Real Goods Solar makes it very convenient for customers to save on their energy bill by providing a comprehensive solar solution, from design, financing, permitting and installation to ongoing monitoring, maintenance and support. As one of the nation’s largest and most experienced solar power players, the company has 14 offices across the West and the Northeast. It services the commercial and utility markets through its RGS Energy division. For more information, visit RealGoodsSolar.com or RGSEnergy.com, on Facebook at http://facebook.com/realgoodssolar and on Twitter at http://twitter.com/realgoodssolar.

Forward-looking Statements
This press release includes forward-looking statements relating to matters that are not historical facts. Forward-looking statements may be identified by the use of words such as “expect,” “intend,” “believe,” “will,” “should” or comparable terminology or by discussions of strategy. While Real Goods Solar believes its assumptions and expectations underlying forward-looking statements are reasonable, there can be no assurance that actual results will not be materially different. Risks and uncertainties that could cause materially different results include, among others, introduction of new products and services, completion and integration of acquisitions, the possibility of negative economic conditions, and other risks and uncertainties included in Real Goods Solar’s filings with the Securities and Exchange Commission. Real Goods Solar assumes no duty to update any forward-looking statements.

CONTACT: Media and Investor Relations Contact:
         Ron Both
         Liolios Group, Inc.
         Tel 1-949-574-3860
         RSOL@liolios.com
Thursday, August 29th, 2013 Uncategorized Comments Off on (RSOL) to Deploy 1.1 MW Solar Power System for Ironhouse Sanitary District

(TSYS) $58.3M Contract Managed Satellite Services for U.S. Marine Corps

First TCS Contract Award under DISA CS2 IDIQ Vehicle

ANNAPOLIS, Md., Aug. 29, 2013 — TeleCommunication Systems, Inc. (TCS) (NASDAQ: TSYS), a world leader in highly reliable and secure mobile communication technology, today announced that it has entered into a contract with the Defense Information Systems Agency (DISA) to provide Managed Satellite Services, Ku satellite bandwidth, terrestrial support and 24-hour support services for the U.S. Marine Corps’ Tactical Satellite Communications Network. The initial funding on this award is $12.8 million for the base 12-month period starting August 1, 2013. The contract includes four, one-year option terms, which, if exercised, have a total contract value of $58.3 million. This contract was issued under the joint DISA/GSA Future Commercial Satcom Acquisition program. TCS is one of eight prime contract awardees under the $2.6 billion Custom SATCOM Solutions (CS2) vehicle, which was awarded in August 2012. The CS2 contract has a base term of three years, ending August 2015 with two subsequent one-year option terms.

News Facts:

  • The U.S. General Services Administration and DISA are managing this procurement through the $2.6 billion Custom SATCOM Solutions (CS2) contract vehicle. This is the first CS2 task order awarded directly to TCS.
  • TCS will be providing the Marine Corps with commercial satellite services to various terminals to extend the Marine Corps Enterprise Network to deployed users.
  • As real-world missions arise, TCS has created a cost-efficient managed services solution through a network of commercial satellite bandwidth pools that has the flexibility to increase bandwidth in one region and decrease bandwidth in another region to support the Marine Corps’ diverse operations.

Supporting Quote:
TCS Government Solutions Group President Michael Bristol, said: “Through our experience with wireless point-to-point links and commercialization projects, the Marine Corps has come to trust TCS TotalCom® solutions. Now, we will provide further highly reliable communication technology to deployed forces.”

TCS has established a proven track record for more than 25 years as a trusted provider of communication technology solutions for the government’s toughest technical challenges, under conditions that demand the highest level of reliability, availability and security. To ensure mission continuity, TCS TotalCom® offers deployable, highly secure communication solutions and complete end-to-end managed services for converged (IP-based) voice, video and data solutions to organizations requiring seamless and secure connectivity between fixed sites and remote operations.

About TeleCommunication Systems, Inc.
TeleCommunication Systems, Inc. (TCS) (NASDAQ: TSYS) is a world leader in highly reliable and secure mobile communication technology. TCS infrastructure forms the foundation for market leading solutions in E9-1-1, text messaging, commercial location and deployable wireless communications. TCS is at the forefront of new mobile cloud computing services providing wireless applications for navigation, hyper-local search, asset tracking, social applications and telematics. Millions of consumers around the world use TCS wireless apps as a fundamental part of their daily lives. Government agencies utilize TCS’ cyber security expertise, professional services, and highly secure deployable satellite solutions for mission-critical communications. Headquartered in Annapolis, MD, TCS maintains technical, service and sales offices around the world. To learn more about emerging and innovative wireless technologies, visit www.telecomsys.com.

Except for the historical information contained herein, this news release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. These statements are subject to risks and uncertainties and are based upon TCS’ current expectations and assumptions that if incorrect would cause actual results to differ materially from those anticipated. Risks include without limitation the possibility that the contract options will not be exercised, that the contract will not be fully funded and those detailed from time to time in the Company’s SEC reports, including the report on Form 10-K for the year ended December 31, 2012 and on Form 10-Q for the quarter ended June 30, 2013.

Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to update or revise the information in this press release, whether as a result of new information, future events or circumstances, or otherwise.

(Logo: http://photos.prnewswire.com/prnh/20120503/PH99996LOGO )

Company Contact: Media Contact: Investor Relations:
TeleCommunication Systems, Inc. Nadel Phelan, Inc. Liolios Group, Inc.
Meredith Allen Graham Sorkin Scott Liolios
410-295-1865 831-440-2406 949-574-3860
MAllen@telecomsys.com graham@nadelphelan.com info@liolios.com
Thursday, August 29th, 2013 Uncategorized Comments Off on (TSYS) $58.3M Contract Managed Satellite Services for U.S. Marine Corps

(SHLO) Reports Third Quarter 2013 Results

VALLEY CITY, OH–(Aug 29, 2013) – Shiloh Industries, Inc. (NASDAQ: SHLO) today reported financial results for the third quarter of its fiscal year ending Oct. 31, 2013.

Third Quarter Highlights:

  • Sales revenue for the quarter ended July 31, 2013 improved 16.9 percent to $166.1 million, from the third quarter a year earlier.
  • Gross profit for the quarter improved over 44 percent from the third quarter a year earlier and was $17.5 million, or 10.5 percent of sales revenue.
  • Operating income for the quarter improved 108 percent to $8.2 million, from the third quarter a year earlier.
  • Net income per share diluted improved 121 percent to $0.31 for the quarter, compared to net income of $0.14 per share diluted from the prior year third quarter.

Third Quarter 2013 Results:

The company reported sales revenue of $166.1 million for the third quarter of fiscal year 2013, an increase of 16.9 percent from $142.0 million in the same quarter of the previous year. Increased revenues are reflective of a 3.8 percent improvement in North American car and light truck industry production volume compared to the third quarter of 2012, new product launches and revenues from acquired companies.

Gross profit for the third quarter improved 44 percent to $17.5 million, or 10.5 percent of sales revenue, compared to $12.2 million or 8.6 percent of sales revenue for the third quarter of 2012. Improved productivity, increased sales volume and reductions in fixed manufacturing expenses contributed to the increase.

For the third quarter of fiscal 2013, operating income improved over 108 percent to $8.2 million, compared to $3.9 million in the third quarter of the previous year.

The company reported net income for the third quarter of fiscal year 2013 of $5.3 million or $0.31 per share diluted, an improvement of 121 percent compared to the third quarter of 2012 net income of $2.4 million or $0.14 per share diluted.

First Nine Months 2013 Results:

Operating income for the first nine months of fiscal 2013 improved approximately 42 percent to $23.8 million, compared to $16.8 million for the first nine months of the previous year. Net income for the first nine months of fiscal 2013 was $15.1 million or $0.89 per share diluted, an improvement of over 50 percent from the prior year’s net income of $9.9 million, or $0.59 per share diluted. The improvement reflects an increase in sales volume of $56.4 million, or 12.9 percent, to sales for the first nine months of fiscal 2013 of $493.6 million and a 29.6 percent improvement in gross margin driven primarily by productivity improvements, the successful integration of acquisitions and smooth product launches.

“Shiloh’s profitability continues to improve not only as revenues increase from higher North American vehicle production levels and new sales growth, but also as a result of our focus on continued productivity improvements,” said Ramzi Hermiz, president and chief executive officer. “As we progress through the remainder of fiscal 2013, we are strategically aligned to take advantage of the improved industry trends and vehicle demand in North America. Our strategy of leading with technology and innovation to become the premier lightweighting and NVH solution provider will be a driving force for our team to move forward with purpose and speed to achieve sustainable, global, profitable growth and world class results.”

Headquartered in Valley City, Ohio, Shiloh Industries provides lightweighting and noise and vibration solutions to automotive, commercial vehicle and other industrial markets through its imaginative thinking and advanced capabilities. Shiloh delivers these solutions through the design, engineering and manufacturing of high-pressure die castings, first operation precision blanks, engineered welded blanks, complex stampings, modular assemblies and its patented ShilohCore™ acoustic laminate metal solution. The company has operations in Alabama, Ohio, Georgia, Michigan, Tennessee, Kentucky, Wisconsin, Indiana and Mexico, and has approximately 1,820 employees. For more information visit www.shiloh.com.

A conference call to discuss third quarter of fiscal 2013 results will be held on Thursday, August 29, 2013, at 11:00 a.m. EDT. To listen to the conference call, dial (888) 576-4398 approximately five minutes prior to the start time and request the Shiloh Industries third quarter conference call.

Certain statements made by Shiloh Industries, Inc. in this release and other periodic oral and written statements, including filings with the Securities and Exchange Commission, regarding the Company’s operating performance, events or developments that the Company believes or expects to occur in the future, including those that discuss strategies, goals, outlook or other non-historical matters, or which relate to future sales, earnings expectations, cost savings, awarded sales, volume growth, earnings or general belief in the Company’s expectations of future operating results are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are made on the basis of management’s assumptions and expectations. As a result, there can be no guarantee or assurance that these assumptions and expectations will in fact occur. The forward-looking statements are subject to risks and uncertainties that may cause actual results to materially differ from those contained in the statements. Some, but not all, of the risks include the ability of the Company to accomplish its strategic objectives with respect to implementing its sustainable business model; the ability to obtain future sales; changes in worldwide economic and political conditions, including adverse effects from terrorism or related hostilities; costs related to legal and administrative matters; the Company’s ability to realize cost savings expected to offset price concessions; the Company’s ability to successfully integrate acquired businesses; inefficiencies related to production and product launches that are greater than anticipated; changes in technology and technological risks; increased fuel and utility costs; work stoppages and strikes at the Company’s facilities and that of the Company’s customers or suppliers; the Company’s dependence on the automotive and heavy truck industries, which are highly cyclical; the dependence of the automotive industry on consumer spending, which is subject to the impact of domestic and international economic conditions, including increased energy costs affecting car and light truck production, and regulations and policies regarding international trade; financial and business downturns of the Company’s customers or vendors, including any production cutbacks or bankruptcies; increases in the price of, or limitations on the availability of, steel, the Company’s primary raw material, or decreases in the price of scrap steel; the successful launch and consumer acceptance of new vehicles for which the Company supplies parts; the occurrence of any event or condition that may be deemed a material adverse effect under the Credit Agreement or a decrease in customer demand which could cause a covenant default under the Credit Agreement; pension plan funding requirements; and other factors, uncertainties, challenges and risks detailed in the Company’s other public filings with the Securities and Exchange Commission. Any or all of these risks and uncertainties could cause actual results to differ materially from those reflected in the forward-looking statements. These forward-looking statements reflect management’s analysis only as of the date of this release.

The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof. In addition to the disclosures contained herein, readers should carefully review risks and uncertainties contained in other documents the Company files from time to time with the Securities and Exchange Commission.

CONTACT:
Thomas M. Dugan
Vice President of Finance and Treasurer
Shiloh Industries, Inc.
(330) 558-2600

Thursday, August 29th, 2013 Uncategorized Comments Off on (SHLO) Reports Third Quarter 2013 Results

(Z) to Participate in the Citi and Deutsche Bank 2013 Technology Conferences

SEATTLE, Aug. 29, 2013 — Zillow, Inc. (Nasdaq:Z), the leading real estate and home-related marketplace, today announced that Zillow®’s Chief Financial Officer Chad Cohen will participate in the Citi 2013 Global Technology Conference on Sept. 3, 2013 at the Hilton New York Hotel, with a fireside chat scheduled to begin at 9:45 a.m. EDT., and that Kathleen Philips, Zillow chief operating officer, and Jeremy Wacksman, vice president of marketing, will participate in the Deutsche Bank Technology Conference on Sept. 10, 2013 at the Cosmopolitan of Las Vegas, with a fireside chat scheduled to begin at 4:10 p.m. PDT.

About Zillow, Inc.

Zillow, Inc. (Nasdaq:Z) operates the leading real estate and home-related information marketplaces on mobile and the Web, with a complementary portfolio of brands and products that help people find vital information about homes, and connect with the best local professionals. Zillow’s brands serve the full lifecycle of owning and living in a home: buying, selling, renting, financing, remodeling and more. In addition, Zillow offers a suite of tools and services to help local real estate, mortgage, rental and home improvement professionals manage and market their businesses. Welcoming more than 61 million monthly unique users in July, the Zillow, Inc. portfolio includes Zillow.com®, Zillow Mobile, Zillow Mortgage Marketplace , Zillow Rentals, Zillow Digs™, Postlets®, Diverse Solutions®, Agentfolio™, Mortech®, HotPads™ and StreetEasy®. Zillow is headquartered in Seattle.

Please visit http://investors.zillow.com/, www.zillowblog.com, www.twitter.com/zillow, and www.facebook.com/zillow, where Zillow discloses information which may be deemed material from time to time about the company, its financial information, and its business.

The Zillow logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=10012.

Zillow.com, Zillow, Postlets, Diverse Solutions, Mortech and StreetEasy are registered trademarks of Zillow, Inc.

Agentfolio, HotPads and Digs are trademarks of Zillow, Inc.

(ZFIN)

CONTACT: Raymond "RJ" Jones
         Investor Relations
         206-470-7137
         ir@zillow.com

         Katie Curnutte
         Public Relations
         206-757-2785
         press@zillow.com
Thursday, August 29th, 2013 Uncategorized Comments Off on (Z) to Participate in the Citi and Deutsche Bank 2013 Technology Conferences

(NSPR) Announces Participation in Two Investor Conferences in September

Presenting at Rodman & Renshaw conference on Tuesday, September 10th Presenting at Stifel Healthcare conference on Thursday, September 12th

BOSTON, Aug. 29, 2013 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), today announced that the management team will present at the following investor conferences:

On Tuesday, September 10th, Alan Milinazzo, President and Chief Executive Officer of InspireMD, will present at the 15th Annual Rodman & Renshaw Global Investment Conference at the Millennium Broadway Hotel in New York City. The Company will present at 2:50 pm ET in Room 7.03, 7th Floor.

Investors unable to attend the Rodman conference may listen in to the webcast, which can be found on the Investors section of the Company’s website at www.inspire-md.com/site_en/for-investors/. The webcast will be available for 90 days following the presentation.

On Thursday, September 12th, Mr. Milinazzo will present at the Stifel Annual Healthcare Conference at the Four Seasons Hotel in Boston, Massachusetts. The Company will present at 3:50 pm ET in the Winthrop room.

Investors attending the conferences who wish to meet with InspireMD management for one-on-one meetings are encouraged to contact their Rodman and Stifel representatives directly or InspireMD Investor Relations at InspireMD@kcsa.com.

A copy of the materials presented at both conferences will be available on the InspireMD investor relations website at www.InspireMD.com.

About Stenting and MGuard™ EPS

Standard stents were not engineered for heart attack patients. They were designed for treating stable angina patients, whose occlusion is different from that of an occlusion in a heart attack patient.

In acute heart attack patients, the plaque or thrombus is unstable and often breaks up as the stent is implanted, causing downstream blockages (some of which can be fatal) in a significant portion of heart attack patients.

The MGuard EPS is integrated with a precisely engineered micro net mesh that prevents the unstable arterial plaque and thrombus (clots) that caused the heart attack blockage from breaking off.

While offering superior performance relative to standard stents in STEMI patients with regard to ST segment resolution, the MGuard EPS requires no change in current physician practice – an important factor in promoting acceptance and general use in time-critical emergency settings.

About InspireMD 

InspireMD seeks to utilize its proprietary MGuard technology to make its products the industry standard for embolic protection stents and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.

InspireMD intends to pursue applications of this technology in coronary, carotid and peripheral artery procedures. InspireMD’s common stock is quoted on the NYSE MKT under the ticker symbol NSPR.

MGuard EPS is CE Mark approved. It is not approved for sale in the U.S. by the FDA at this time.

Forward-Looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) our limited manufacturing capabilities and reliance on subcontractors for assistance, (vii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (viii) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (ix) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (x) our reliance on single suppliers for certain product components, (xi) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Transition Report on Form 10-K/T and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Investor Contacts:
Todd Fromer / Garth Russell
KCSA Strategic Communications
Phone: 212-896-1215 / 212-896-1250
Email: tfromer@kcsa.com / grussell@kcsa.com

Media Contacts:
Lewis Goldberg / Samantha Wolf
KCSA Strategic Communications
Phone: 212-896-1216 / 212-896-1220
Email: lgoldberg@kcsa.com / swolf@kcsa.com

Thursday, August 29th, 2013 Uncategorized Comments Off on (NSPR) Announces Participation in Two Investor Conferences in September

(ENTR) Jiuzhou Integrates c.LINK 1.1 Ethernet Over Coax Broadband Access Solution

Jiuzhou HD-STB, Embedded With Entropic’s Silicon, Enables Chinese Cable Subscribers to Enjoy Advanced, High-Definition Video on Demand Services

SAN DIEGO, Aug. 28, 2013  — Entropic (Nasdaq:ENTR), a world leader in semiconductor solutions for the connected home, announced today its c.LINK® 1.1 Ethernet over Coax (EoC) Broadband Access solution has been integrated into high definition (HD) set-top boxes (STBs) from leading Chinese STB manufacturer, Sichuan Jiuzhou Electronic Technology Co., LTD, (Jiuzhou). By embedding Entropic’s c.LINK silicon and software into a single HD-STB, operators can get better scale from their broadband access network and more quickly and cost-effectively offer Video-on-Demand (VOD) services.

Cable operators throughout China are looking for complete, end-to-end video and broadband access solutions. By using the Jiuzhou STBs integrated with Entropic’s c.LINK technology, operators can capitalize on the stability of their c.LINK EoC network infrastructure and accelerate VOD service deployments.

“To offer value-added VOD services and other advanced IP-based video services, Chinese operators require a rich, robust connectivity backbone,” said Jia Biming, general manager, Jiuzhou. “By leveraging Entropic’s c.LINK solution in both the STB and the broadband access infrastructure, subscribers are certain to get a faster, more exciting video viewing experience.”

“Interactive, or two-way set-top boxes, are the key to increase ARPU,” said Tom Luan, vice president and general manager, China operations, Entropic. “Jiuzhou’s new generation HD-STB advances the use of our c.LINK technology – progressing it forward from its traditional broadband access modem use case to a video-specific set-top box that will expedite MSOs’ NGB initiatives, increase their ARPU and reduce overall operational expenses.”

About the Entropic c.LINK 1.1 EoC Solution

Entropic’s c.LINK 1.1 EoC solution is based on the EN3511 Network Controller (NC) and the EN3530 Client Premise Equipment (CPE). Key technical features include:

  • Reliability – based on the field proven MoCA® (Multimedia over Coax) 1.1 chipset technology, for which Entropic has already shipped more than 50-million MoCA 1.0/1.1 chipsets;
  • Lower Total Systems Cost – achieved through its highly integrated 65nm single-chip SoC and optimized bill of materials (BOM) costs;
  • Increased Performance – providing more than 270 Mbps of raw data bandwidth and more than 175 Mbps of application throughput;
  • Backward Compatibility – to the currently deployed system (EN3011/EN3230) in the field offering a seamless upgrade path; and
  • Support for Quality of Service (QoS) Performance Attributes – with high immunity to electrical interference and stringent low latency time-division-multiplexing protocol (TDM).

Availability

The Jiuzhou HD-STB samples will be available in Q3 2013, with production in Q4 2013.

About Sichuan Jiuzhou Electronic Technology Co.,LTD.

Sichuan Jiuzhou Electronic Technology Co., Ltd is set up and owned by Sichuan Jiuzhou Electric Group Co., Ltd. They specialize in R&D and the manufacture of CATV equipment.

Jiuzhou has been in the CATV industry since 1958. With 50 years of development, they have expanded from analog equipment into DVB digital TV head-end equipment and fiber optic transmission equipment. All production processes are controlled and supervised according to ISO9001 standards.

In order to keep up with the latest developments, Jiuzhou has set up R&D centers in Mianyang, Beijing, and Shenzhen. Besides its own R&D centers, Jiuzhou also maintains close cooperation with leading science institutes in China and abroad. Jiuzhou products are currently exported to Europe, South America, South Asia, Middle East, etc.

About Entropic

Entropic™ (Nasdaq:ENTR) is a world leader in semiconductor solutions for the connected home. The Company transforms how traditional HDTV broadcast and IP-based streaming video content is seamlessly, reliably, and securely delivered, processed, and distributed into and throughout the home. Entropic’s next-generation Set-top Box (STB) System-on-a-Chip (SoC) and Connectivity solutions enable Pay-TV operators to offer consumers more captivating whole-home entertainment experiences by transforming the way digital entertainment is delivered, connected and consumed – in the home and on the go. For more information, visit Entropic at: www.entropic.com.

The Entropic logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4255

Forward Looking Statements

Statements in this press release that are not strictly historical in nature constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Entropic’s EoC technologies, its related prospects and its role in the future of connected home entertainment. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause Entropic’s actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, competition, risks associated with Entropic dependence on a limited number of customers and suppliers, technology risks, the risk that the market for HD video and multimedia content delivery solutions may not develop as Entropic anticipates and other factors discussed in the “Risk Factors” section of Entropic’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2013. All forward-looking statements are qualified in their entirety by this cautionary statement. Entropic is providing this information as of the date of this release and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Copyright© 2013 Entropic. All rights reserved. All other product or company names mentioned are used for identification purposes only and may be trademarks of their respective owners.

CONTACT: Entropic Investor Contact:
         Debra Hart
         +1 858-768-3852
         debra.hart@entropic.com

         Entropic Media/Industry Analyst Contact:
         Chris Fallon
         +1 858-768-3827
         chris.fallon@entropic.com
Wednesday, August 28th, 2013 Uncategorized Comments Off on (ENTR) Jiuzhou Integrates c.LINK 1.1 Ethernet Over Coax Broadband Access Solution

(GOGO) Introduces In-Flight Smartphone Calling and Texting

Gogo Text & Talk service allows passengers to call and text via Wi-Fi in flight, using their own smartphone and mobile number Company also adds voice capabilities to existing Gogo Biz service

BROOMFIELD, Colo., Aug. 28, 2013 — Aircell (NASDAQ: GOGO), a leading provider of in-flight connectivity equipment and services to the business aviation market, announces that its Gogo Biz service will expand to include voice capabilities, beginning October 1st. Gogo Biz was originally launched in 2009 as an Internet-only service in the business aviation market.

(Logo: http://photos.prnewswire.com/prnh/20130415/CG94789LOGO)

Because Gogo Biz operates on Aircell’s air-to-ground technology, its voice calls are among the clearest in aviation – on par with mobile phone calls on the ground. As a “two-in-one” service, Gogo Biz offers Internet and voice capabilities from a single system, which can eliminate the need for separate systems, dramatically reducing equipment requirements and installation costs.

Monthly voice plans for Gogo Biz start at $134.95/month, which includes 60 voice minutes.

In flight, passengers and flight crews can use the new Gogo Biz voice capabilities on their own smartphones and/or with Aircell’s new cabin handsets, as detailed below:

  1. Gogo Text & Talk. Your Own Smartphone, Your Own Number
    Gogo Text & Talk is an exclusive new service that allows passengers to use their own smartphones for calling and texting in flight – with their own mobile number.It’s easy to use because it mimics the native features and operation of the passenger’s smartphone. Passengers can use their own contact lists and hands-free devices. Features like Caller ID and call histories are supported. Calling someone in flight is as simple as dialing their number.

    Gogo Text & Talk is a game-changing service because it operates over Wi-Fi technology (not cellular) and uses the passenger’s own mobile number (not an auto-attendant, two-step dialing or call-forwarding protocol). Because the service is 100% software-based, it can be added to any standard Gogo Biz equipment package without additional hardware, weight or installation downtime. This makes Gogo Text & Talk practical for aircraft as small as light jets and turboprops – while being hundreds of thousands of dollars less expensive than traditional, picocell-based solutions, which offer similar capabilities.

    Available with any Gogo Biz system, Gogo Text & Talk is obtained by purchasing a software key for the aircraft’s onboard equipment and installing a free app on passengers’ smartphones. The service will be available for iPhone 4, 4S and 5 beginning October 1st. Support for select Android devices will begin on November 1st. More information is available at www.aircell.com/gogotexttalk.

  2. The Gogo OnePhone.  Aircell’s Next-Generation Cabin Handset
    The new Gogo OnePhone offers superior voice quality and the industry’s most advanced noise reduction technology. Its big, bright, touchscreen display and Android-based operating system mean it’s very easy to use. High-end industrial design and carefully-chosen finishes and materials make it a perfect complement to any business aircraft interior. Wired and wireless options are available.Shipments of the Gogo OnePhone will begin October 15th. More information is available at www.aircell.com/gogoonephone.

John Wade, Aircell’s Executive Vice President and General Manager, commented, “Although in-flight Internet has captured the world’s interest in recent years, customers never stopped asking for the ability to use their own smartphone – with their own number – to call and text while they fly. We firmly believe in the future of in-flight voice service and the role it plays in our ‘always on’ lifestyles. With today’s introduction of voice capabilities for Gogo Biz, a new cabin handset and the ability to use personal smartphones, customers have more options than ever.”

NOTES TO EDITORS

Two images accompany this release:

Image 1: Gogo Text & Talk

Image 2: The Gogo OnePhone

About Aircell
Aircell, a Gogo company, is a leading provider of in-flight connectivity equipment and services to the business aviation market. Through a full range of services including voice, high-speed Internet, cockpit data and more, Aircell increases the productivity, safety, and enjoyment of the business aviation travel experience. Headquartered in Broomfield, Colorado, USA, Aircell is an AS9100-certified company serving a global customer base with an authorized dealer/distributor network that spans six continents. A trusted brand in airborne communications, Aircell is a factory option at every major business aircraft manufacturer and installed on the world’s largest fractional ownership fleets. The only company to offer equipment for three of the industry’s most popular network technologies – Iridium Satellite, Inmarsat SwiftBroadband and Gogo Biz®, Aircell provides advice and solutions addressing any customer need, aircraft type, or geography.

A Collier Trophy nominee and the recipient of several dozen awards for innovation, Aircell is widely credited with many of the industry’s most influential historical achievements, beginning with the groundbreaking airborne cellular concept that launched the company in 1991. Connect with us at www.aircell.com and on Twitter at www.twitter.com/aircellbizav.

© 2013 Aircell. All rights reserved. Aircell, Gogo and Gogo Biz, and In Touch, In Flight are trademarks of Aircell Business Aviation Services LLC or its affiliates. Third-party trademarks are the property of their respective owners. Not endorsed by any smartphone device manufacturers or distributors.

Press Contact:
Tom Myers
Director, Marketing
Office +1.303.301.3237
tmyers@aircell.com
www.twitter.com/aircellbizav

Wednesday, August 28th, 2013 Uncategorized Comments Off on (GOGO) Introduces In-Flight Smartphone Calling and Texting

(KEQU) Increases Quarterly Dividend

STATESVILLE, N.C., Aug. 28, 2013 — Kewaunee Scientific Corporation (Nasdaq: KEQU) announced today its Board of Directors increased its quarterly cash dividend by 10% to eleven cents per outstanding share from ten cents per outstanding share, beginning with the dividend payable on September 24, 2013 to stockholders of record at the close of business on September 10, 2013.

Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. Laboratory furniture products include both steel and wood cabinetry, fume hoods, adaptable modular systems, moveable workstations, biological safety cabinets, and epoxy resin counters and sinks. Healthcare furniture products include laminate casework, storage systems, and related products for healthcare applications. Technical furniture products include column systems, slotted-post systems, pedestal systems, and stand-alone benches.

The Company’s corporate headquarters are located in Statesville, North Carolina. Three manufacturing facilities are located in Statesville, NC serving the domestic and international markets. One manufacturing facility is located in Bangalore, India serving the local and Asian markets. The Company has subsidiaries in Singapore and India. Kewaunee Scientific’s website is located at http://www.kewaunee.com.

Contact: D. Michael Parker
704/871-3290
Wednesday, August 28th, 2013 Uncategorized Comments Off on (KEQU) Increases Quarterly Dividend

(OTIV) Directors Buying Stock

ROSH PINA, Israel, Aug. 28, 2013 — On Track Innovations Ltd. (OTI) (Nasdaq:OTIV), a global provider of near field communication (NFC) and cashless payment solutions, reports several members of its board of directors have been actively buying OTI ordinary shares in the open market (pursuant to Rule 10b5-1 plans executed in June 2013 and/or during open trading windows pursuant to OTI’s insider trading policy). OTI was advised these purchases total approximately 735,000 shares to date. OTI’s directors will be required to report their holdings and changes in ownership of OTI securities by filing Forms 3, 4 and/or 5 starting on January1, 2014, when OTI will commence reporting as a domestic issuer and will no longer be entitled to report as a foreign private issuer.

About On Track Innovations

On Track Innovations Ltd. (OTI) is a leader in contactless and NFC applications based on its extensive patent and IP portfolio. OTI’s field-proven innovations have been deployed around the world to address NFC payment solutions, petroleum payment and management, cashless parking fee collection systems and mass transit ticketing. OTI markets and supports its solutions through a global network of regional offices and alliances. For more information, visit www.otiglobal.com.

CONTACT: OTI Contact:
         Galit Mendelson
         VP, Corporate Relations
         732 429 1900 ext. 111
         galit@otiglobal.com

         Investor Contact:
         Scott Liolios or Matt Glover
         Liolios Group, Inc.
         949 574 3860
         otiv@liolios.com
Wednesday, August 28th, 2013 Uncategorized Comments Off on (OTIV) Directors Buying Stock

(ASTX) Topline Results SGI-110 AML Phase 2 Myeloid Leukemia Study

DUBLIN, Calif., Aug. 28, 2013 — Astex Pharmaceuticals, Inc. (Nasdaq:ASTX) today announced topline results from the ongoing phase 2 of SGI-110 in patients with AML and MDS. The Phase 2 study is a randomized study of SGI-110 given either as 60 or 90 mg/m2 daily for 5 days in a 28-day course. As of end of June data cutoff, 67 AML patients had a minimum follow up of 3 months (50 patients representing the complete cohort of relapsed/refractory AML, and 17 patients in the treatment-naive elderly AML not suitable for induction chemotherapy cohort). The primary endpoint is overall remission rate (Complete Remission or CR; Complete Remission with Incomplete hematologic recovery or CRi/CRp). There were 8 remissions in relapsed/refractory AML and 9 remissions in treatment-naive elderly AML for an overall complete remission rate (CR, CRi/CRp) of 17/67 or 25%. The detailed results have been submitted for presentation to the American Society of Hematology (ASH) meeting to be held later this year during December 7-10 in New Orleans, LA.

About SGI-110

SGI-110 is a novel small molecule, DNA-hypomethylating agent administered as a single low volume subcutaneous injection. SGI-110 demonstrated activity in restoring silenced tumor suppressor gene expression in cancer cells by reversal of DNA methylation and inducing responses in previously treated MDS and AML patients. SGI-110 is wholly owned by Astex Pharmaceuticals.

About Astex Pharmaceuticals

Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology. The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals developed and out-licensed DACOGEN® (decitabine) for Injection and receives significant royalties on global sales.

For more information about Astex Pharmaceuticals, Inc., please visit http://www.astx.com.

CONTACT: Timothy L. Enns
         Astex Pharmaceuticals, Inc.
         Senior Vice President
         Corporate Communications & Marketing
         Tel: +1 (925) 560-2810
         E-mail: tim.enns@astx.com

         Susanna Chau
         Astex Pharmaceuticals, Inc.
         Manager
         Investor Relations
         Tel: +1 (925) 560-2845
         E-mail: susanna.chau@astx.com

         Alan Roemer
         The Trout Group
         Managing Director
         Tel: +1 (646) 378-2945
         E-mail: aroemer@troutgroup.com
Wednesday, August 28th, 2013 Uncategorized Comments Off on (ASTX) Topline Results SGI-110 AML Phase 2 Myeloid Leukemia Study

(ANLY) to Acquire Analysts International Corp. for $35M ($6.45/share)

ATLANTA, GA and MINNEAPOLIS, MN–(Aug 28, 2013) – American CyberSystems, Inc. (ACS), a global information technology services company, and Analysts International Corporation (AIC) (NASDAQ: ANLY), a leading information technology services company, today announced they have signed a definitive agreement under which ACS will acquire AIC in a transaction valued at approximately $35.0 million. Under terms of the agreement, ACS will commence a tender offer for all outstanding shares of AIC for $6.45 per share, in cash, which is a 62.1 percent premium over the average closing price for AIC over the past 30 days. AIC’s Board of Directors unanimously approved the transaction and recommends that AIC’s shareholders accept ACS’s offer.

“American CyberSystems continues to experience tremendous growth in the marketplace. The acquisition of AIC allows us to accelerate our plans for growth in specific desirable geographies and capitalize on marquee customer opportunities,” said Raj Sardana, ACS Chairman and CEO. “The AIC legacy of service excellence will remain intact and will be a strong complement to ACS and our combined customer base.”

“This merger is good for our customers, employees and shareholders,” said Brittany McKinney, AIC President and CEO. “By combining our strengths with the added capabilities and resources of ACS, AIC will continue to provide the same high value services our customers have come to expect from us, while expanding our offerings, delivery capabilities and geographic reach to better serve them. Our employees will become part of a larger organization that provides expanded career opportunities and a broader network of colleagues with a shared passion for customer service. And our shareholders will receive an immediate cash payment at a substantial premium to AIC’s average recent stock price,” concluded McKinney.

Details Regarding the Proposed AIC Acquisition
Under the terms of the transaction, ACS will commence a tender offer to acquire all of the outstanding shares of AIC for $6.45 per share in cash. Closing of the offer is subject to satisfaction of a 60 percent minimum tender condition, receipt of funding under ACS’s financing commitments, the absence of a material adverse effect on AIC and other customary conditions. Following completion of the tender offer, ACS will complete a second-step merger to convert remaining AIC shares into cash at the $6.45 per share price. In the event that the tender offer conditions are not met, the parties have agreed to complete the transaction through a one-step merger, subject to the receipt of AIC shareholder approval. Following the closing of the merger, AIC will become a privately-held company, wholly owned by ACS. ACS plans to continue to operate the company under the AIC brand.

The transaction is expected to close in the fourth quarter. For additional information regarding the terms and conditions contained in the definitive acquisition agreement, please see AIC’s Current Report on Form 8-K, which will be filed in connection with the transaction.

ACS is being advised by McKenna Long & Aldridge LLP. Advisors for AIC are Cherry Tree & Associates, LLC and Faegre Baker Daniels LLP.

About American CyberSystems, Inc.
Founded in 1998, American CyberSystems, Inc. is a global information technology services company offering IT consulting and staffing services, systems integration and business solutions to organizations in a variety of industries. Through its extensive resource pool and global recruitment centers, ACS offers unparalleled expertise in delivering solutions for Fortune 1000 companies worldwide. ACS works in partnership with clients to understand their challenges, share their vision and deliver mission specific solutions. For more information about American CyberSystems, please visit http://www.acsicorp.com/.

About Analysts International Corporation
Analysts International Corporation is an IT services firm fully dedicated to the success and satisfaction of its clients. From IT staffing to project-based solutions, AIC provides a broad range of services designed to help businesses and government agencies drive value, control costs and deliver on the promise of a more efficient and productive enterprise. AIC offers a flexible, collaborative approach; clear industry perspective; and the breadth, scale and experience to deliver results. For more information, visit http://www.analysts.com/Pages/default.aspx.

Notice to Investors
The tender offer for the outstanding shares of AIC common stock described in this press release has not yet commenced. This press release is neither an offer to purchase nor a solicitation of an offer to sell securities. The solicitation and the offer to buy shares of AIC’s common stock will be made pursuant to an offer to purchase and other related materials that a wholly owned subsidiary of ACS (Merger Sub) and ACS expect to file with the U.S. Securities and Exchange Commission (SEC). At the time the tender offer is commenced, Merger Sub and ACS will file a tender offer statement on Schedule TO (including an offer to purchase, a related letter of transmittal, and other tender offer documents) with the SEC, and AIC will file with the SEC a solicitation/recommendation statement on Schedule 14D-9 with respect to the tender offer. Shareholders of AIC are strongly advised to read the tender offer statement (including an offer to purchase, a related letter of transmittal and other tender offer documents) and the related solicitation/recommendation statement when they become available because they will contain important information that AIC shareholders should consider before making any decision regarding tendering their shares. These materials (and all other materials filed by AIC with the SEC) will be available to all shareholders of AIC at no expense to them on the SEC’s website at www.sec.gov. Free copies of the tender offer statement and related materials and the solicitation/recommendation statement, when available, may be obtained from the information agent for the tender offer or from the “Investor Relations” section of the AIC website at www.analysts.com.

Forward-Looking Statements
This press release contains forward-looking statements that are not historical facts and are subject to risks and uncertainties that could cause actual results to differ materially from those described. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Without limiting the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate” or “continue,” or comparable terminology, are intended to identify forward-looking statements. Forward-looking statements in this press release include statements regarding the anticipated benefits of the transaction; statements regarding the anticipated timing of filings and approvals relating to the transaction; statements regarding the expected timing of the completion of the transaction; and any statements of assumptions underlying any of the foregoing. All forward-looking statements are based largely on current expectations and beliefs concerning future events, approvals and transactions that are subject to substantial risks and uncertainties. Factors that may cause or contribute to the actual results or outcomes being different from those contemplated by forward-looking statements include: risks and uncertainties associated with the tender offer, including uncertainties as to the timing of the tender offer and merger, uncertainties as to how many of AIC’s shareholders will tender their shares in the offer, the risk that competing offers will be made, and the possibility that various closing conditions for the transaction may not be satisfied or waived. Other factors that may cause AIC’s actual results to differ materially from those expressed or implied in the forward-looking statements are discussed in AIC’s filings with the SEC, including in its periodic reports filed on Form 10-K and Form 10-Q with the SEC. Such factors include (i) the risk that management may not fully or successfully implement its business plan or maintain profitability in the future; (ii) the risk that AIC will not be able to realize the benefits of its investments or exploit other opportunities of the business in a timely manner or on favorable terms; (iii) prevailing market conditions in the IT services industry, including intense competition for billable technical personnel at competitive rates, strong pricing pressures from many of our largest clients and difficulty in identifying, attracting and retaining qualified billable technical personnel; (iv) potentially incorrect assumptions by management with respect to the financial effect of prior cost reduction initiatives and current strategic decisions; and (v) other economic, business, market, financial, competitive and/or regulatory factors affecting AIC’s business generally, including those set forth in AIC’s filings with the SEC. Copies of AIC’s filings with the SEC may be obtained at the “Investor Relations” section of AIC’s website at www.analysts.com. The forward-looking statements made in this release are made only as of the date of this release, and AIC undertakes no obligation to update them to reflect subsequent events or circumstances.

The Information Agent for the Offer is Alliance Advisors. Please call toll free: 855-325-6670.
Banks & Brokers call: 973-873-7721 or E-mail: reorg@allianceadvisorsllc.com

Media Contacts:
Clara Abdurazak
American CyberSystems, Inc.
678.553.8930
Email Contact

Marne Oberg
Analysts International Corporation
952.838.2867
Email Contact

Wednesday, August 28th, 2013 Uncategorized Comments Off on (ANLY) to Acquire Analysts International Corp. for $35M ($6.45/share)

(REED) Reed’s Culture Club Kombucha Now Available at Kroger Supermarkets

Reed’s Kombucha Expands Presence Into 1000 Kroger Supermarkets Nationally

Reed’s Kombucha Expands Presence Into 1000 Kroger Supermarkets Nationally

LOS ANGELES, CA–(Aug 27, 2013) – Reed’s, Inc. (NYSE MKT: REED), maker of the top-selling sodas in natural food stores nationwide, announced today that the The Kroger Company (NYSE: KR) chain of supermarkets has agreed to begin carrying four flavors of Reed’s Culture Club Kombucha in approximately 1,000 of their supermarkets across the US. Some of the store banners that will begin carrying our Kombucha are, Kroger, Ralph’s, Fred Meyer, Dillon’s, Smith’s and Fry’s.

Chris Reed, Founder and CEO of Reed’s Inc., stated, “We continue to grow our partnership with Kroger nationally. Kroger, the largest supermarket chain in the U.S., determined that consumer demand for Kombucha and probiotic beverages in the mainstream supermarket channel is expanding rapidly. We are excited by our Kombucha being authorized. In general, we are pleasantly surprised by the strong interest from the supermarket industry for our Kombucha and had not anticipated entering mainstream supermarkets so fast. We have quickly become the number two selling Kombucha company nationwide. We look forward to developing the Kombucha category with Kroger and driving sales.”

About The Kroger Company 

The Kroger Co. is one of the world’s largest grocery retailers, with fiscal 2012 sales of $96.8 billion. Kroger’s Family of Stores spans many states with store formats that include grocery and multi-department stores, discount, convenience stores and jewelry stores. We operate under nearly two dozen banners, all of which share the same belief in building strong local ties and brand loyalty with our customers. www.kroger.com

About Reed’s, Inc.

Reed’s, Inc. makes the top-selling natural sodas in the natural foods industry sold in over 13,000 natural food markets and supermarkets nationwide. Its six award-winning non-alcoholic Ginger Brews are unique in the beverage industry, being brewed, not manufactured and using fresh ginger, spices and fruits in a brewing process that predates commercial soft drinks. The Company owns the top-selling root beer line in natural foods, the Virgil’s Root Beer product line, and the top-selling cola line in natural foods, the China Cola product line. In 2012, the Company launched Reed’s Culture Club Kombucha line of organic live beverages. Other product lines include: Reed’s Ginger Candies and Reed’s Ginger Ice Creams. In 2009, Reed’s started producing private label natural beverages for select national chains. Reed’s products are sold through specialty gourmet and natural food stores, mainstream supermarket chains, retail stores and restaurants nationwide, and in Canada, as well as through private label relationships with major supermarket chains.

For more information about Reed’s, please visit the Company’s website at: http://www.reedsinc.com or call 800-99-REEDS.

Follow Reed’s on Twitter at http://twitter.com/reedsgingerbrew

Reed’s Facebook Fan Page at https://www.facebook.com/ReedsGingerBrew

SAFE HARBOR STATEMENT
Some portions of this press release, particularly those describing Reed’s goals and strategies, contain “forward-looking statements.” These forward-looking statements can generally be identified as such because the context of the statement will include words, such as “expects,” “should,” “believes,” “anticipates” or words of similar import. Similarly, statements that describe future plans, objectives or goals are also forward-looking statements. While Reed’s is working to achieve those goals and strategies, actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. These risks and uncertainties include difficulty in marketing its products and services, maintaining and protecting brand recognition, the need for significant capital, dependence on third party distributors, dependence on third party brewers, increasing costs of fuel and freight, protection of intellectual property, competition and other factors, any of which could have an adverse effect on the business plans of Reed’s, its reputation in the industry or its expected financial return from operations and results of operations. In light of significant risks and uncertainties inherent in forward-looking statements included herein, the inclusion of such statements should not be regarded as a representation by Reed’s that they will achieve such forward-looking statements. For further details and a discussion of these and other risks and uncertainties, please see our most recent reports on Form 10-K and Form 10-Q, as filed with the Securities and Exchange Commission, as they may be amended from time to time. Reed’s undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Tuesday, August 27th, 2013 Uncategorized Comments Off on (REED) Reed’s Culture Club Kombucha Now Available at Kroger Supermarkets

(GFN) to Announce Q4 and FY13 Financial Results on September 9

PASADENA, Calif., Aug. 27, 2013 — General Finance Corporation (Nasdaq:GFN), the parent company of businesses in the mobile storage, modular space and liquid containment industries (the “Company”), will announce its financial results for the fourth quarter and fiscal year ended June 30, 2013 before the U.S. market opens on Monday, September 9, 2013.

Management will host a conference call the same day at 8:30 a.m. PDT (11:30 a.m. EDT) to discuss the Company’s operating results. The conference call number for U.S. participants is (866) 901-5096 and the conference call number for participants outside the U.S. is (706) 643-3717. The conference ID number for both conference call numbers is 36634799. Additionally, interested parties can listen to a live webcast of the call in the “Investor Relations” section of the Company’s website at http://www.generalfinance.com.

A replay of the conference call may be accessed through September 23, 2013 by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (international), using conference ID number 36634799.  

After the replay has expired, interested parties can listen to the conference call via webcast in the “Investor Relations” section of the Company’s website at http://www.generalfinance.com.

About General Finance Corporation

Headquartered in Pasadena, California, General Finance Corporation (Nasdaq:GFN) (www.generalfinance.com) is the parent company of businesses in the mobile storage, modular space and liquid containment (“portable services”) industries. Management’s expertise in these sectors drives disciplined growth strategies, operational guidance, effective capital allocation and capital markets support for the Company’s subsidiaries. The Company’s principal operating subsidiaries are majority-owned Royal Wolf Holdings Limited (www.royalwolf.com.au), the leading provider of portable storage solutions in the Asia-Pacific regions of Australia and New Zealand, wholly-owned Pac-Van, Inc. (www.pacvan.com), a prominent regional provider of portable storage, office and liquid storage tank containers, mobile offices and modular buildings in North America, and 90%-owned Southern Frac, LLC (www.southernfrac.com), a domestic manufacturer of portable liquid storage tank containers. Royal Wolf’s shares trade on the Australian Securities Exchange under the symbol RWH.

Cautionary Statement about Forward-Looking Statements

Statements in this news release that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements addressing management’s views with respect to future financial and operating results, competitive pressures, market interest rates for our variable rate indebtedness, our ability to raise capital or borrow additional funds, changes in the Australian, New Zealand or Canadian dollar relative to the U.S. dollar, regulatory changes, customer defaults or insolvencies, litigation, acquisition of businesses that do not perform as we expect or that are difficult for us to integrate or control, our ability to procure adequate levels of products to meet customer demand, adverse resolution of any contract or other disputes with customers, declines in demand for our products and services from key industries such as the Australian mining industry or the U.S. construction industry or a write-off of all or a part of our goodwill and intangible assets. These involve risks and uncertainties that could cause actual outcomes and results to differ materially from those described in forward-looking statements. We believe that the expectations represented by our forward-looking statements are reasonable, yet there can be no assurance that such expectations will prove to be correct. Furthermore, unless otherwise stated, the forward-looking statements contained in this press release are made as of the date of the press release, and we do not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise unless required by applicable law. The forward-looking statements contained in this press release are expressly qualified by this cautionary statement. Readers are cautioned that these forward-looking statements involve certain risks and uncertainties, including those contained in filings with the Securities and Exchange Commission.

CONTACT: Investor/Media Contact

         Larry Clark
         Financial Profiles, Inc.
         310-478-2700 ext. 29
Tuesday, August 27th, 2013 Uncategorized Comments Off on (GFN) to Announce Q4 and FY13 Financial Results on September 9

(CCCR) Issues Positive Outlook for Coming Year

WUJIANG, CHINA–(Marketwired – Aug 27, 2013) – China Commercial Credit, Inc. (NASDAQ: CCCR), a microcredit company providing loans and loan guarantees to small-to-medium sized enterprises (SMEs), farmers and individuals, today issued a corporate outlook for the next 12 months. Mr. Huichun Qin, founder and CEO, cited three primary factors expected to fuel the company’s growth:

  • CCC’s improved access to capital to increase its lending capacity.
  • Continuing expansion of the microcredit industry, in both China and Jiangsu Province, where the company is based.
  • Ongoing government measures making the microcredit sector more attractive to borrowers.

CCC’s improved access to capital. As a result of raising $8.9 million in its recent IPO — thereby becoming the first China-based microcredit company to go public in the U.S. — China Commercial Credit is expected to increase its available lending capital from $98 million (RMB 600 million) to $130 million (RMB 800 million). This, in turn, should positively impact the company’s interest revenue in the near term, said Mr. Qin.

Mr. Qin, a former Deputy Director of Peoples Bank of China (PBOC) — the nation’s Central Bank — added that, with its Nasdaq listing, CCC has the option to raise additional equity or issue debt in the U.S. and Hong-Kong, thereby further increasing its lending capacity and accelerating company growth.

Continuing expansion of the microcredit industry. According to recent PBOC data, at the end of June 2013 there were 7,086 microcredit companies in China, compared to only 1,940 three years ago. Since June 2010, microcredit companies’ outstanding loans have multiplied by 5.6 times to $115 billion (RMB 704 billion).

Jiangsu Province has seen the fastest growth of any province in China during this period, with the number of microcredit firms rising 4.3 times to 529, and outstanding loans growing six times to $18 billion (RMB 109 billion). Wujiang City, CCC’s base, remains one of the most economically successful cities in China, said Mr. Qin, and is home to an increasing number of the world’s leading exporters of electronic equipment, chemicals and textiles — many of which require microfinance loans.

This growth is primarily due to the Chinese government’s 2008 financial reforms to ease the country’s reliance on lending by State-owned banks — which had heavily favored lending to State-owned enterprises and large companies — and allow the creation of microcredit companies designed to serve the borrowing needs of SMEs, farmers and individuals, a group accounting for eight out of ten jobs in China and comprising 60 percent of that nation’s GDP.

Since 2008, microcredit companies have played an increasingly important role in financing SMEs nationwide and especially in Jiangsu Province, said Mr. Qin. And because most State-owned banks in China — due to higher costs and risks — are still not willing to lend to SMEs, the growth of the microcredit industry will likely accelerate for the foreseeable future, he added.

Ongoing government measures. Three recent policy changes by the Chinese government will likely spur the growth of the microcredit industry, said Mr. Qin. The first are the credit tightening measures, enacted in June 2013, currently affecting the nation’s State-owned banks. These measures, which could last for as much as a year, will likely drive additional loan applicants — including many State-owned enterprises and larger companies — into the microcredit sector, said Mr. Qin.

The second policy change is the increased government pressure to restrict the activities of private, high interest underground lenders, many of whom have charged SMEs 50 percent interest or more. This excessive interest rate, said Mr. Qin, has caused many SMEs to fail and has produced severe inflationary pressures throughout the economy.

Lastly, the government has also taken steps to curtail off-balance sheet “back-door” bank loans to SMEs. These steps will likely continue, said Mr. Qin, driving further loan business into the microcredit sector.

Due to the above factors, Mr. Qin said he expected CCC could experience “improved revenue and profit growth” over last year’s results beginning in the fourth quarter of this year.

For the last 12 months through March 31, 2013, China Commercial Credit had a profit of $8.3 million on approximately $12 million in interest and fee revenue. Since inception, CCC has delivered net revenue and pre-tax income with compound annual growth rates of 22% and 34%, respectively. This rapid growth, said Mr. Qin, is a “strong indication” of China’s financial support for SMEs.

“It is an honor to be the first Chinese microcredit company to go public and list on a U.S. national exchange,” concluded Mr. Qin. “I deeply appreciate the interest that investors are showing in one of China’s lesser known but superior growth industries. I am excited about the future of microfinance in general and CCC specifically, and I look forward to communicating our progress to shareholders on a regular basis.”

About China Commercial Credit
China Commercial Credit (http://www.chinacommercialcredit.com), founded in 2008, provides business loans and loan guarantee services to more than 360 small-to-medium enterprises (SMEs), farmers and individuals in China’s Jiangsu Province. Due to recent legislation and banking reform in China, these SMEs, farmers and individuals – which historically had been excluded from borrowing funds from State-owned and commercial banks — are now able to borrow money at competitive rates from microfinance lenders.

Investors wishing to receive CCC’s corporate communications as they become available may go to http://www.ir-site.com/china-commercial-credit/default.asp and register under Email Alerts.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws. You should not rely upon forward-looking statements as predictions of future events. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this release to conform these statements to actual results or to changes in our expectations. You should review the factors described in the section entitled “Risk Factors” in our prospectus filed with the SEC on August 14, 2013 and other documents we file from time to time with the SEC. We qualify all of our forward-looking statements by these cautionary statements.

Contact Information:

Investors
Jimmy Caplan
Market Makers
512-329-9505
jimmycaplan@me.com

Media
Rick Eisenberg
Eisenberg Communications
212-496-6828
eiscom@msn.com

Tuesday, August 27th, 2013 Uncategorized Comments Off on (CCCR) Issues Positive Outlook for Coming Year

(HITK) to Be Acquired By Akorn for $640 Million

– Over $500 million in combined revenues – – Immediately accretive to non-GAAP earnings, before synergies – – $15-20 million in annual run-rate synergies expected within 12 months post-close – – Strong combined cash flow allows for rapid pay-down of debt –

Akorn, Inc. (NASDAQ: AKRX) and Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today announced that they have entered into a definitive agreement under which Akorn will acquire Hi-Tech for $640 million in cash.

Hi-Tech is a specialty pharmaceutical company developing, manufacturing and marketing generic and branded prescription and over-the-counter (OTC) products. Hi-Tech specializes in difficult to manufacture liquid and semi-solid dosage forms and produces and markets a range of oral solutions and suspensions, as well as topical ointments and creams, nasal sprays, otics, sterile ophthalmics and sterile ointment and gels products. Hi-Tech’s Health Care Products division is a leading developer and marketer of OTC products. Hi-Tech’s ECR Pharmaceuticals subsidiary markets branded prescription products.

Under the terms of the agreement, Akorn will pay $640 million in cash, or $43.50 per share. This represents a 23.5% premium over the closing price on August 26. Akorn expects to achieve between $15 million and $20 million in annual run-rate synergies within 12 months of close. The combined company is expected to have annual revenues in excess of $500 million and the transaction is expected to be accretive to Akorn’s non-GAAP adjusted earnings per share immediately upon closing. Assuming the transaction occurred on January 1, 2013 and assuming the full realization of synergies, the acquisition would have been approximately 40% accretive to Akorn’s expected 2013 non-GAAP adjusted earnings per share.

Raj Rai, Akorn’s Chief Executive Officer, commented, “This is a transformative event for our company. The portfolio of Hi-Tech products is a great strategic fit to our currently marketed products as it diversifies our offering to our retail customers beyond ophthalmics to other niche dosage forms such as oral liquids, topical creams and ointments, nasal sprays and otics. In addition, we are excited about Hi-Tech’s product pipeline which would further enhance growth opportunities for the combined platform.”

Rai further added, “The acquisition of Hi-Tech will also add branded OTC products in the categories of cough & cold, nasals, and topicals to Akorn’s existing TheraTears® brand of eye care products. We also plan to capitalize on the manufacturing capabilities of Hi-Tech to further expand our presence in the private label OTC business.”

Hi-Tech’s Chief Executive Officer, David Seltzer, said, “We are excited about the transaction as it delivers compelling value to our shareholders. The combined portfolio of marketed products and products in development offer a very unique platform with great growth potential. We are very pleased to be joining forces with Akorn and their strong management team led by Raj Rai.”

Key Benefits of the Transaction

Creates a larger, more diversified specialty generics player

The combination strengthens Akorn’s current position as the third largest U.S. generic ophthalmic player, and broadens the product offering to include other niche dosage forms such as oral liquids, topical creams and ointments, nasal sprays and otics. Also, this transaction significantly increases Akorn’s retail presence in both prescription and OTC products.

Expands Pipeline

Akorn currently has 57 abbreviated new drug applications (ANDAs) filed with the U.S. Food and Drug Administration (FDA) with a combined annual addressable IMS market size of approximately $5.6 billion. Hi-Tech has 18 filed ANDAs with a combined annual addressable IMS market size of approximately $2.6 billion.

Financially Compelling and Immediately Accretive

The transaction is expected to be accretive to non-GAAP earnings immediately upon closing, before synergies. Assuming the transaction occurred on January 1, 2013 and assuming the full realization of synergies, the acquisition would have been approximately 40% accretive to Akorn’s expected 2013 non-GAAP adjusted earnings per share.

Significant Synergies Expected

Akorn expects to achieve between $15 million and $20 million in annual synergies through operating efficiencies.

Strong Combined Cash Flow Allows for Rapid Debt Repayment

Upon closing, the combined company will have a strong balance sheet and attractive cash flow, giving it financial flexibility to pursue continued growth initiatives while paying down debt.

Transaction Terms

Under the terms of the agreement, Akorn will acquire Hi-Tech for $640 million, or $43.50 per share. Akorn intends to fund the transaction through a combination of Hi-Tech cash assumed and approximately $600 million in term loan borrowings. As of the fiscal year-ended April 30, 2013, Hi-Tech had $100.6 million in cash and cash equivalents. Fully committed financing for the transaction has been provided by JPMorgan Chase Bank, N.A.

Approval and Timing

The acquisition will be subject to customary conditions, including termination of the waiting period under the provisions of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. Pending the satisfaction of such customary conditions, Akorn anticipates closing the transaction in the first quarter of 2014.

J.P. Morgan Securities LLC is acting as exclusive financial advisor and Kirkland & Ellis LLP and Polsinelli PC are acting as legal advisors to Akorn in connection with this transaction. Nomura Securities International, Inc. is acting as exclusive financial advisor and Arent Fox LLP and Tashlik Goldwyn Crandell Levy LLP are acting as legal advisors to Hi-Tech in connection with this transaction.

Conference Call

Akorn will host a conference call, with supporting slides available via webcast, beginning at 10:00 a.m. Eastern Time on August 27, 2013 to discuss the proposed acquisition. The dial-in numbers to access the call are U.S./Canada 888-523-1225; International 719-457-2648. The Conference ID is 6176966. The slides can be accessed through the Investor Relations page of Akorn’s website at http://www.akorn.com/news.php, or at http://www.videonewswire.com/event.asp?id=95749. A live broadcast of the conference call will also be available online at the Investor Relations page of Akorn’s website for 30 days.

About Akorn, Inc.

Akorn, Inc. is a niche pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals with a focus on sterile ophthalmic and injectables. Akorn has finished dose manufacturing facilities located in Decatur, Illinois, Somerset, New Jersey and Paonta Sahib, India.

About Hi-Tech Pharmacal Co., Inc.

Hi-Tech is a specialty pharmaceutical company developing, manufacturing and marketing generic and branded prescription and OTC products. The Company specializes in difficult to manufacture liquid and semi-solid dosage forms and produces a range of sterile ophthalmic, otic and inhalation products. Hi-Tech’s Health Care Products division is a leading developer and marketer of OTC products for the diabetes marketplace. Hi-Tech’s ECR Pharmaceuticals subsidiary markets branded prescription products.

Forward Looking Statements

Certain statements in this press release are “forward-looking statements” under Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are based on current expectations. However, actual results may differ materially from expectations due to the risks, uncertainties and other factors that affect our business and Hi-Tech’s business. These factors include, among others, the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement; the failure to satisfy conditions to completion of the Merger, including receipt of regulatory approvals; changes in the business or operating prospects of Hi-Tech; our ability to obtain additional funding or financing to operate and grow our business; the effects of federal, state and other governmental regulation on our business; our ability to obtain and maintain regulatory approvals for our products; our success in developing, manufacturing, acquiring and marketing new products; the success of our strategic partnerships for the development and marketing of new products; our ability to successfully integrate acquired businesses and products; and the effects of competition from other generic pharmaceuticals and from other pharmaceutical companies. We and Hi-Tech provide additional information about these and other factors in the reports filed with the Securities and Exchange Commission, including, but not limited to, those described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our and Hi-Tech’s annual reports on Form 10-K for the year ended December 31, 2012 and April 30, 2013, respectively. Except as required by applicable law, we disclaim any obligation to update any forward-looking statement in this document, whether as a result of changes in underlying factors, new information, future events or otherwise.

Important Additional Information and Where to Find It

In connection with the proposed transaction, Hi-Tech intends to file a proxy statement with the Securities and Exchange Commission (SEC) and mail it to its stockholders. Stockholders of Hi-Tech are urged to read the proxy statement and the other relevant material when they become available because they will contain important information about Hi-Tech, Akorn, the proposed transaction and related matters. STOCKHOLDERS OF HI-TECH ARE URGED TO CAREFULLY READ THE PROXY STATEMENT AND THE OTHER RELEVANT MATERIALS WHEN THEY BECOME AVAILABLE BEFORE MAKING ANY VOTING OR INVESTMENT DECISION WITH RESPECT TO THE PROPOSED MERGER. The proxy statement and other relevant materials (when available), and any and all documents filed by Hi-Tech with the SEC, may also be obtained for free at the SEC’s website at www.sec.gov. In addition, investors and security holders may obtain free copies of the documents filed with the SEC by Hi-Tech by directing a written request to Hi-Tech, Attention: William Peters, Chief Financial Officer, 369 Bayview Avenue, Amityville, NY 11701.

This announcement is neither a solicitation of proxy, an offer to purchase nor a solicitation of an offer to sell shares of Hi-Tech. Hi-Tech, its executive officers and directors may be deemed to be participants in the solicitation of proxies from the security holders of Hi-Tech in connection with the proposed merger. Information about those executive officers and directors of Hi-Tech and their ownership of Hi-Tech common stock is set forth in the Hi-Tech proxy statement for its 2012 Annual Meeting of Stockholders, which was filed with the SEC on September 28, 2012, and its Annual Report on Form 10-K for the year ended April 30, 2013, which was filed with the SEC on July 11, 2013. These documents may be obtained for free at the SEC’s website at www.sec.gov, and from Hi-Tech by contacting Hi-Tech, Attention: William Peters, Chief Financial Officer, 369 Bayview Avenue, Amityville, NY 11701. Additional information regarding the interests of participants in the solicitation of proxies in connection with the transaction will be included in the proxy statement that Hi-Tech intends to file with the SEC.

Tuesday, August 27th, 2013 Uncategorized Comments Off on (HITK) to Be Acquired By Akorn for $640 Million

(CPRX) Receives Breakthrough Therapy Designation From FDA

CORAL GABLES, Fla., Aug. 27, 2013 — Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, today announced that its investigational product Firdapse™ (amifampridine phosphate) has received “Breakthrough Therapy Designation” by the U.S. Food and Drug Administration (FDA) for the symptomatic treatment of patients with Lambert-Eaton Myasthenic Syndrome (LEMS). Firdapse™ is Catalyst’s investigational therapy that is being evaluated for the treatment of the debilitating symptoms associated with LEMS, including muscle weakness.

“We are very pleased to have received Breakthrough Therapy Designation for Firdapse™ and we are excited by the FDA’s decision to place our product in a category that may enable expedited development and review for patients with LEMS,” said Patrick McEnany, President and Chief Executive Officer of Catalyst. “With no approved or effective symptomatic treatment currently available for LEMS, Firdapse™ has the potential to be the first-line treatment option for patients with this rare condition.”

Breakthrough Therapy Designation for Firdapse™ was based on clinical data from several previously published clinical trials of amifampridine (3,4-DAP) in patients with LEMS. Firdapse™ has the potential to provide significant relief of the often debilitating symptoms of the disease, including muscle weakness (e.g. difficulty walking), difficulty swallowing and talking, drooping of eyelids and facial weakness.

About Breakthrough Therapy Designation

Breakthrough Therapy Designation was enacted as part of the 2012 Food and Drug Administration Safety and Innovation Act (FDASIA). FDASIA defines breakthrough therapy as a drug that is “intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.”

A breakthrough therapy designation conveys all of the fast track program features, as well as more intensive FDA guidance on an efficient drug development program. The FDA also has an organizational commitment to involve senior management in such guidance. The Breakthrough Therapy Designation is a distinct status from both accelerated approval and priority review, which can also be granted to the same drug if relevant criteria are met.

About Firdapse™

Firdapse™, also known as amifampridine phosphate, 3,4-diaminopyridine phosphate or 3,4-DAP phosphate, is a potassium channel blocker. It delays repolarization of the pre-synaptic neuron, causing voltage gated Ca2+ channels to remain open longer. The increase Ca2+ influx causes more acetylcholine to be released, making it more likely that a muscle action potential will be initiated, thereby reducing muscle weakness. The North American rights to Firdapse™ were licensed to the Company in 2012 by BioMarin Pharmaceutical. BioMarin currently markets Firdapse™ in the EU for the treatment of LEMS.

In the United States, where the product has previously received orphan drug designation, Firdapse™ is in a Phase III, multicenter, double-blind, placebo-controlled, randomized discontinuation study followed by an open-label extension period to evaluate the efficacy and safety of Firdapse™ in patients with LEMS. In addition to LEMS, other potential orphan neuromuscular indications for Firdapse™ include Myasthenia Gravis and Congenital Myasthenic Syndrome, among others.

About LEMS

Lambert-Eaton Myasthenic Syndrome, LEMS, is a rare autoimmune disease that can be severely disabling, with the primary symptom of muscle weakness. The weakness is generally more marked in the proximal muscles, particularly of the legs and trunk. Other problems include reduced reflexes, drooping of the eyelids, facial weakness and problems with swallowing. Patients often report dry mouth, impotence, constipation and feelings of light headedness on standing. These problems can be life threatening when the weakness involves respiratory muscles. The muscle weakness in LEMS is caused by autoantibodies to voltage gated calcium channels, which cause a reduction in the amount of acetylcholine released from nerve terminals. The prevalence of LEMS is estimated at approximately 3,000 patients in the United States and Canada. Approximately 50 percent of LEMS patients diagnosed have small cell lung cancer. Patients with LEMS typically present with fatigue, muscle pain and stiffness. A diagnosis of LEMS is generally made on the basis of clinical symptoms, electromyographic and compound muscle action potential (CMAP) testing and where available, the presence of autoantibodies against voltage gated calcium channel.

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a specialty pharmaceutical company focused on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette Syndrome. Catalyst’s lead candidate, Firdapse™ for the treatment of LEMS, is currently undergoing testing in a global, multi-center, pivotal phase III trial. Catalyst is also developing a potentially safer and more potent vigabatrin analog (designated CPP-115) to treat infantile spasms, and epilepsy, as well as other neurological conditions associated with reduced GABAergic signaling, like post-traumatic stress disorder and Tourette Syndrome.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst’s actual results in future periods to differ materially from forecasted results. A number of factors, including the timing of completion of Catalyst’s currently ongoing Phase III trial of Firdapse™, whether the Phase III trial will be successful, whether the receipt of breakthrough therapy designation for Firdapse™ will expedite the development and review of Firdapse™ by the FDA or the likelihood that the product will be found to be safe and effective, whether an NDA for Firdapse™ will ever be accepted for filing by the FDA, the timing of any such NDA filing or acceptance, whether any of Catalyst’s product candidates will ever be approved for commercialization or successfully commercialized, and those other factors described in Catalyst’s Annual Report on Form 10-K for the fiscal year 2012 and other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst’s filings with the SEC are available from the SEC, may be found on Catalyst’s website or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

CONTACT: For Further Information Contact:
         Patrick J. McEnany
         Catalyst Pharmaceutical Partners
         Chief Executive Officer
         (305) 529-2522
         pmcenany@catalystpharma.com

         Melody Carey
         Rx Communications Group
         Co-President
         (917) 322-2571
         mcarey@rxir.com
Tuesday, August 27th, 2013 Uncategorized Comments Off on (CPRX) Receives Breakthrough Therapy Designation From FDA

(PTCT) New Evidence Published In Muscular Dystrophy

-Two publications further validate the use of 6MWT as a primary endpoint in Duchenne Muscular Dystrophy (DMD) clinical trials-

SOUTH PLAINFIELD, N.J., Aug. 26, 2013 – Data published in the medical journal Muscle & Nerve demonstrate the clinical meaningfulness of the 6-minute walk test (6MWT) as a primary endpoint to measure disease progression and walking ability in ambulatory Duchenne muscular dystrophy (DMD) trials. The research also showed that a range of 20 to 30 meters in walking ability is a clinically meaningful change, as measured by 6-minute walk distance (6MWD). This analysis is based on natural history data obtained from PTC Therapeutics’ Phase 2b trial of ataluren in 174 patients with nonsense mutation Duchenne muscular dystrophy (nmDMD), the first placebo-controlled, multi-national study of a new chemical entity for DMD.

“Given that several novel approaches to the treatment of Duchenne muscular dystrophy have shown promise in preclinical and/or proof-of-concept clinical studies, the research community has faced the need to identify and develop clinically meaningful outcome measures for use in pivotal therapeutic trials. In boys with DMD, walking abnormalities are a major disease manifestation that have great importance to patients and their families,” stated Dr. Craig McDonald, one of the world’s leading experts in muscular dystrophy clinical endpoints and DMD natural history studies and lead author of the two publications. “We pioneered the development of the 6MWT for DMD with PTC in conjunction with the ataluren trials and I am pleased to have collaborated with the ataluren study group to demonstrate the 6MWT as a reliable, valid, and meaningful endpoint for Duchenne muscular dystrophy.” Dr. McDonald added, “The data from the ataluren placebo group has recently been replicated in other natural history studies conducted by investigators in Belgium and Italy. All three data sets show a similar change in 6-minute walk distance over one year as a measure of disease progression.”

The 6MWT was originally developed as an integrated assessment of cardiac, respiratory, circulatory and muscular capacity, and it has previously been used as a primary outcome in a number of clinical studies to support the regulatory approval of treatments for a number of other neuromuscular disorders. In a prior short-term study (McDonald et al 2010), the 6MWT was established as a feasible, safe and reliable outcome measure of walking ability in boys with DMD, who have not yet transitioned to full-time wheelchair use. A follow-up longitudinal study concluded that changes in 6MWD depend on stride length and age. Improvements in 6MWD were observed in both healthy subjects and patients with DMD <7 years of age, attributed to maturational development. In contrast, the walking ability of older DMD patients (≥7 years of age) worsened, while the walking ability of older healthy subjects (≥7 years of age) tended to either increase or remain stable. Subsequent studies have confirmed this observation and also demonstrated that 6MWD correlates with other clinical endpoints in DMD, such as timed function tests and the North Star Ambulatory Assessment (NSAA), as well as established patient-reported outcomes of physical function.

“In our Phase 2b Duchenne muscular dystrophy trial, we did not have any natural history to guide our inclusion criteria. The patient population was quite heterogeneous ranging in age from 5 to 20 years old and the baseline 6-minute walk distance ranged from 75 meters to 554 meters,” stated Stuart W. Peltz, Ph.D., Chief Executive Officer at PTC Therapeutics, Inc. “Armed with a better understanding of the natural history of the disease, the enrollment criteria for our ongoing Phase 3 trial now enriches the patient population that are in the decline phase of walking ability and would best demonstrate benefit in a 48-week trial. When we looked back at the subgroup of 61 patients from our completed Phase 2b trial that fit the inclusion criteria of the current trial, they showed an average 50 meter improvement in ambulation as measured in the 6-minute walk distance from patients on placebo. We anticipate that the Phase 3 trial will complete enrollment mid-2014.”

This report in Muscle & Nerve represents an evaluation of the largest multicenter dataset collected to date to determine the reliability and concurrent validity of the 6MWT and other clinical endpoints in DMD. In addition, the research assesses the distribution-based MCID (minimal clinically important difference) for 6MWD and other commonly-employed functional endpoints (eg. timed function tests and quantitative knee extension strength measures) as well as the 6MWD, which is the most common primary endpoint for ambulatory DMD clinical trials. Moreover, baseline walking ability, as measured by the 6MWD was found to be predictive of time to ≥10% worsening in function, a clinically meaningful milestone, in DMD.

The research findings confirm that the 6MWT is a safe and feasible measure of walking ability in DMD and a valid primary outcome measure for ambulatory DMD clinical trials. In addition, the data supports the clinically meaningful change in walking ability, as measured by 6MWT, to be in the range of 20 to 30 meters, which can serve as a targeted treatment effect in 12-month trials in ambulatory DMD.

About the Publications
The natural history data were derived from the placebo arm of a Phase 2b, international, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of ataluren in ambulatory male patients with nonsense mutation DMD aged ≥5 years. The other publication analyzes the baseline data from all DMD patients in the same Phase 2b study. The study comprised a 6-week screening period and a 48-week blinded study drug treatment period. Patients were randomized 1:1:1 to receive: ataluren at either high- or low-dose or matching placebo, daily for 48 weeks. Evaluations were performed at screening, baseline, and every 6 weeks for 48 weeks.

There were 174 randomized DMD patients included in the study. All patients screened and randomized were males, ranging in age from 5 to 20 years. Nonsense mutations were distributed across the span of the 79 exons of the dystrophin gene, with no mutational hotspots identified, and represented all three types of premature stop codons. Test-retest reliability was determined using the baseline and screening values for all endpoints. Concurrent validity and MCIDs were determined using pre-treatment data.

About Duchenne Muscular Dystrophy (DMD)
Primarily affecting males, Duchenne muscular dystrophy (DMD) is a progressive muscle disorder caused by the lack of functional dystrophin protein. Dystrophin is critical to the structural stability of skeletal, diaphragm, and heart muscles. Patients with Duchenne muscular dystrophy, the more severe form of the disorder, lose the ability to walk as early as age 10 and experience life-threatening lung and heart complications in their late teens and twenties. There are an estimated 34,000 patients with DMD in the United States and Europe and approximately 13 percent of all DMD cases are caused by nonsense mutations in the dystrophin gene. More information about DMD is available through the Muscular Dystrophy Association (www.mdausa.org), Parent Project Muscular Dystrophy (www.parentprojectmd.org), Action Duchenne (www.actionduchenne.org), United Parent Projects Muscular Dystrophy (uppmd.org), Muscular Dystrophy Campaign (www.muscular-dystrophy.org) and AFM (l’Association francaise contre les myopathies), (www.afm-telethon.fr).

About PTC Therapeutics, Inc. (NASDAQ:PTCT)
PTC is biopharmaceutical company focused on the discovery and development of orally-administered, proprietary small molecule drugs that target post-transcriptional control processes. While PTC’s discovery programs are directed at targets in multiple therapeutic areas, PTC is focusing particularly on the development and commercialization of treatments for orphan and ultra-orphan disorders. Post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. PTC’s internally-discovered pipeline addresses multiple therapeutic areas, including neuromuscular disorders, oncology and infectious diseases. For more information on the company, please visit our website www.ptcbio.com.

Forward Looking Statements:
Any statements in this press release about future expectations, plans and prospects for PTC, including statements about enrollment and conduct of PTC’s Phase 3 clinical trial of ataluren for nmDMD, the clinical meaningfulness of the 6MWT for regulatory purposes and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,”  and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Forward-looking statements involve substantial risks and uncertainties that could cause our future results, performance or achievements to differ significantly from those expressed or implied by these forward-looking statements. Such risks and uncertainties include, among others, those related to the initiation and conduct of clinical trials, availability of data from clinical trials, expectations for regulatory approvals, our scientific approach and general development progress, the availability or commercial potential of our product candidates and other factors discussed in the “Risk Factors” section of the final prospectus for our initial public offering, which is on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent PTC’s views only as of the date of this release. PTC anticipates that subsequent events and developments will cause its views to change. However, while PTC may elect to update these forward-looking statements at some point in the future, PTC specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing PTC’s views as of any date subsequent to the date of this release.

Monday, August 26th, 2013 Uncategorized Comments Off on (PTCT) New Evidence Published In Muscular Dystrophy

(ENOC) Achieves Latest OpenADR Certification

Positions EnerNOC for Further Penetration of International Demand Response Market

BOSTON, Aug. 26, 2013  — EnerNOC, Inc. (Nasdaq:ENOC), a leading provider of energy intelligence software, today announced that its technology has been certified by the OpenADR Alliance for compliance with the OpenADR 2.0 Profile B specification. Profile B is designed for high-end embedded devices that support a wide range of demand response services and markets, and this certification confirms EnerNOC’s ability to seamlessly integrate with demand response programs in new and existing markets that require standards compliance. EnerNOC is one of the first companies in the OpenADR Alliance to announce a 2.0B-compliant product.

“International markets have started to design and implement demand response programs and infrastructure, and are looking to standards such as OpenADR 2.0B to accelerate growth. We believe we are well-positioned to leverage these global opportunities,” said Hugh Scandrett, Vice President of Engineering at EnerNOC. “This certification marks another step in EnerNOC’s continued mission to provide fast, reliable automated demand response to our utility and commercial, institutional, industrial, and agricultural partners, and further validates demand response as a cost-effective, integral part of a modern energy infrastructure.”

Fully automated demand response (AutoDR) streamlines the communication and signaling surrounding a demand response dispatch such that building management systems can respond in seconds to signals from a utility or provider such as EnerNOC. Deploying a standards-based approach like OpenADR helps to lower the cost of enabling AutoDR resources.

EnerNOC has been a member of the OpenADR Alliance since 2010, and currently holds a position on the Alliance’s Board of Directors. EnerNOC is also on the Board of Directors of the Smart Grid Interoperability Panel of the National Institute of Standards and Technology (NIST).

To learn more about EnerNOC’s technology and its commitment to open standards, go to enernoc.com/our-technology or visit open.enernoc.com.

About EnerNOC

EnerNOC is a leading provider of energy intelligence software and related solutions. EnerNOC unlocks the full value of energy management for utility and commercial, institutional, and industrial (C&I) customers by delivering a comprehensive suite of demand-side management services that reduce real-time demand for electricity, increase energy efficiency, improve energy supply transparency in competitive markets, and mitigate emissions. EnerNOC’s Utility Solutions™ offerings, which include both implementation and consulting services, are helping hundreds of utilities and grid operators worldwide meet their demand-side management objectives. EnerNOC serves thousands of commercial, institutional, and industrial customers worldwide through a suite of energy management applications including: DemandSMART™, comprehensive demand response; EfficiencySMART™, continuous energy savings; and SupplySMART™, energy price and risk management. EnerNOC’s Network Operations Center (NOC) offers 24x7x365 customer support. For more information, visit www.enernoc.com.

The EnerNOC, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5804

Safe Harbor Statement

Statements in this press release regarding management’s future expectations, beliefs, intentions, goals, strategies, plans or prospects, including, without limitation, statements relating to the technological capabilities associated with the Company’s energy intelligence software, and the benefits that may be derived from that software, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements can be identified by terminology such as “anticipate,” “believe,” “could,” “could increase the likelihood,” “estimate,” “expect,” “intend,” “is planned,” “may,” “should,” “will,” “will enable,” “would be expected,” “look forward,” “may provide,” “would” or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to under the section “Risk Factors” in EnerNOC’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, as well as other documents that may be filed by EnerNOC from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company’s actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. EnerNOC is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Media Relations: Sarah McAuley
         (617) 532.8195, news@enernoc.com
         Investor Relations: Brian Norris
         (617) 532.8104, ir@enernoc.com
Monday, August 26th, 2013 Uncategorized Comments Off on (ENOC) Achieves Latest OpenADR Certification